Subcutaneous dosing of Anti-CD38 antibodies
Patent Information
- Application Number
- JP2023218600
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-03-28
- Filing Date
- 2023-12-25
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current anti-CD38 antibodies require high doses and intravenous administration due to binding to red blood cells, leading to side effects such as hemolytic anemia and thrombocytopenia, making subcutaneous administration impractical.
Development of anti-CD38 antibodies with specific CDR sequences (SEQ ID NO: 3-8) for subcutaneous administration, reducing side effects and allowing for lower, more convenient dosages.
Subcutaneous administration of these antibodies effectively targets CD38-expressing cells with reduced side effects, providing therapeutic benefits for autoimmune diseases and hematological cancers.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 649,489, filed March 28, 2018, which is incorporated by reference in its entirety.
[0002] Methods and compositions for administering an isolated anti-CD38 antibody via subcutaneous (SC) administration are disclosed. [Background technology]
[0003] CD38 (also known as cyclic ADP-ribose hydrolase) is a type II transmembrane glycoprotein with a long C-terminal extracellular domain and a short N-terminal cytoplasmic domain. CD38 is a member of a group of related membrane-bound or soluble enzymes that includes CD157 and Aplysia ADPR cyclase. This family of enzymes has the unique ability to convert NAD to cyclic ADP-ribose or nicotinic acid-adenine dinucleotide phosphate. CD38 is a Ca 2+ CD38 is involved in signal transduction via recruitment of CD38 and tyrosine phosphorylation of multiple signaling molecules, including phospholipase Cγ, ZAP-70, syk, and c-cbl. Based on these observations, CD38 is a key signaling molecule in the maturation and activation of lymphoid cells during their normal development. Among hematopoietic cells, a variety of functional effects have been attributed to CD38-mediated signaling, including control of lymphocyte proliferation, cytokine release, development and survival of B-cells and myeloid cells, and induction of dendritic cell (DC) maturation.
[0004] CD38 is expressed on immature hematopoietic cells, downregulated on mature hematopoietic cells, and re-expressed at high levels on activated lymphocytes and plasma cells. For example, high expression of CD38 is found on activated B cells, plasma cells, activated CD4+ T cells, activated CD8+ T cells, NK cells, NKT cells, mature DCs, and activated monocytes (see, e.g., U.S. Patent No. 8,362,211).
[0005] The presence of autoantibodies against CD38 has been associated with several diseases, including diabetes, chronic autoimmune thyroiditis, and Graves' disease (see Antonelli et al. (2001) Clin. Exp. Immunol. 126:426-431, Mallone et al. (2001) Diabetes 50:752, and Antonelli et al. (2004) J. Endocrinol. Invest. 27:695-707).
[0006] Increased expression of CD38 has been reported in a variety of diseases, including autoimmune diseases and cancer. Such diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and ulcerative colitis (UC). Patients with RA have increased plasma cells in joint tissues compared to controls. Patients with SLE have increased plasmablasts in peripheral blood in patients with more active disease. Current CD20-based B cell depletion therapies, such as rituximab, effectively deplete CD20+ B cells, but cannot directly and effectively deplete plasma cells or plasmablasts, as they do not express CD20. Consistent with this idea, RA or SLE patients with high levels of plasma cells or plasmablasts are unlikely to derive substantial clinical benefit from CD20-based therapies. Therefore, therapeutic agents targeting CD38, which is highly expressed on plasma cells and plasmablasts as well as NK cells and activated T cells, may provide effective treatments for RA and SLE, as well as other diseases characterized by CD-38 expression.
[0007] In particular, increased expression of CD38 has been reported in various diseases of hematopoietic origin and cell lines derived therefrom, and has been described as a negative prognostic marker in blood cancer.Such diseases include but are not limited to multiple myeloma (MM), chronic lymphoblastic leukemia, B-cell chronic lymphocytic leukemia (B-CLL), including B-cell acute lymphocytic leukemia, B-cell and T-cell acute lymphocytic leukemia (ALL), acute lymphoblastic leukemia, Waldenstrom's macroglobulinemia, mantle cell lymphoma, prolymphocytic / myeloid leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), follicular lymphoma, NK cell leukemia, plasma cell leukemia, non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), T-cell lymphoma (TCL), hairy cell leukemia (HCL) and Hodgkin's lymphoma (HL). Furthermore, CD38 expression is a prognostic indicator for patients with conditions such as B-CLL (Durig et al. (2002) Leukemia 16:30-35, and Morabito et al. (2001) Leukemia Res. 25:927-932), and acute myeloid leukemia (Keyhani et al. (1999) Leukemia Res. 24:153-159). Thus, CD38 provides a useful target in the treatment of diseases of the hematopoietic system.
[0008] Several anti-CD38 antibodies are undergoing clinical trials for the treatment of CD38-associated cancers. However, all prior art therapeutic antibodies against CD38 bind to red blood cells (RBCs) and platelets, leading to higher dosage requirements due to non-productive binding to RBCs. Although CD38 is expressed on RBCs at levels approximately 1000 times lower than on myeloma cells (deWeers et al. (2011) J. Immunol. 186(3):1840-1848), there are approximately 36,000 RBCs for each myeloma cell in the blood of MM (multiple myeloma) patients with active disease (Witzig et al. (1993) Cancer 72(1):108-113). Thus, 36 times more CD38 molecules are expressed on RBCs than on tumor cells. Thus, current treatment with anti-CD38 antibodies requires intravenous administration, as high doses are required to achieve efficacy beyond RBC binding. For example, daratumumab (anti-CD38 IgG1 mAb, DARZALEX®, FDA approved and commercially available from Janssen Oncology) requires very high doses (≧16 mg / kg) and an intensive regime (8 times weekly, 8 times biweekly, then monthly) to obtain optimal antitumor activity (Xu et al. (2017) Clin. Pharmacol. Ther. 101(6):721-724).
[0009] Thus, treatment with anti-CD38 antibodies that bind to RBCs is currently focused on intravenous administration, as high doses of antibody are required to achieve therapeutic efficacy, and such large volumes are not suitable for subcutaneous administration. For example, daratumumab cannot be administered at low doses, as target saturation requires ≧16 mg / kg (e.g., approximately 1120 mg for a 70 kg patient). The highest known subcutaneous formulation concentration is 200 mg / ml (Cimzia®, also called cetrizumab pegol). Using the highest known subcutaneous formulation concentration of 200 mg / ml, the minimum expected injection volume of daratumumab would be 5.6-11.2 mL, a very large volume for subcutaneous administration. Given this large volume and concentration limitation, daratumumab must be administered subcutaneously in a 15 ml volume with hyaluronidase to aid in dispersion and absorption.
[0010] Isatuximab, another anti-CD38 antibody (commercially available from Sanofi Genzyme and currently undergoing Phase 3 clinical trials), has been dosed at 10 mg / kg and 20 mg / kg in Phase 3 trials, which corresponds to 700-1400 mg for a 70 kg patient. Again, using the highest known subcutaneous formulation concentration of 200 mg / mL, the expected injection volume of isatuximab would be 3.5-14 mL.
[0011] In addition to requiring higher doses and volumes, prior art anti-CD38 antibodies in current clinical practice can target RBCs and platelets, causing severe side effects such as hemolytic anemia (a condition in which RBCs are destroyed more rapidly than they can be replenished). In an open-label, single-arm study, isatuximab was administered intravenously to a total of 97 patients at 3 mg / kg every 2 weeks (Q2W, n=23), 10 mg / kg Q2W for two cycles followed by Q4W (n=25), 10 mg / kg Q2W (n=24), and 20 mg / kg weekly for four doses (1 cycle) followed by Q2W (n=25). The most common severe (grade 3 / 4) adverse event was anemia, which affected 24% of patients (see http: / / www.onclive.com / conference-coverage / asco-2016 / isatuximab-monotherapy-effective-for-heavily-pretreated-myeloma, the 2016 ASCO Annual Meeting, and Richter et al. (2016) J. Clin. Oncol. 34(suppl):abstr 8005). In addition to severe anemia, thrombocytopenia and neutropenia were also common severe adverse events (22.9%, 18.4%, and 18.4%, respectively, Dimopoulos et al. (2018) Blood 132(suppl.1):ASH abstract 155 / oral presentation). Similarly, low blood counts (WBC, RBC, and platelets), anemia, and thrombocytopenia are well-known serious side effects to daratumumab. In one daratumumab trial, 45% of all patients experienced anemia (19% of which were grade 3) and 48% of patients experienced thrombocytopenia (10% of which were grade 3 and 8% of which were grade 4) (see, for example, Darzalex (daratumumab) prescribing information Horsham, Pennsylvania: Janssen Biotech, Inc. 2018, as well as the review article Costello (2017) Ther. Adv. Hematol. 8(1):28-37). Furthermore, intravenous administration of therapeutic monoclonal antibodies can lead to severe infusion-related reactions (IRR). Common IRRs include, but are not limited to, nasal congestion, cough, allergic rhinitis, throat irritation, dyspnea, chills, nausea, hypoxia, and hypertension (Usmani et al. (2016) Blood 128(1):37-44). With daratumumab, 48% of patients experienced an IRR with the first dose of the drug (Usmani et al. (2016) Blood 128(1):37-44), of which 3% were severe (Darzalex (daratumumab) prescribing information Horsham, Pennsylvania: Janssen Biotech, Inc 2018). Similarly, IRRs were reported in 40.4% of patients receiving isatuximab, of which 4.6% were reported as severe (Dimopoulos et al. (2018)Blood 132:(suppl 1)ASH abstract 155 / oral presentation). Therefore, patients being treated with isatuximab or daratumumab must be closely monitored for these life-threatening and other serious side effects.
[0012] AB79 has a high affinity (Kd = 6.1 × 10 -10 AB79 is a fully human immunoglobulin IgG1 monoclonal antibody that specifically binds to CD38 at 100-fold increase in CD38 expression. AB79 inhibits the growth of tumor cells expressing CD38 by cell depletion via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). AB79 also reduces the levels of plasma cells and plasmablasts in blood isolated from healthy subjects and patients with systemic lupus erythematosus (SLE) (PCT Application No. PCT / US2017 / 042128). In healthy cynomolgus monkeys, the efficiency of depletion for each cell type was positively correlated with the level of CD38 expression and AB79 dose level (PCT Application No. PCT / US2017 / 042128). Furthermore, AB79 has demonstrated anti-inflammatory and disease-modifying activity in monkey models of rheumatoid arthritis (US Patent No. US8,362,211).
[0013] Considering that many CD38 antibodies in clinical settings bind to RBCs and are therefore not suitable for subcutaneous administration, which have dangerous side effects, there remains a need in the art for safer, more convenient and more effective subcutaneous antibody formulations for the treatment of diseases in which binding to CD38 is indicated, such as autoimmune diseases and hematological forms of cancer. Summary of the Invention
[0014] Provided herein are methods for treating diseases in which binding to CD38 is indicated, such as autoimmune diseases and hematological cancers, comprising subcutaneous administration of an isolated anti-CD38 antibody.
[0015] In one aspect, the invention provides a method of treating a disease in a subject for which binding to CD38 is indicated, the method comprising the step of subcutaneously administering to a subject having a disease for which binding to CD38 is indicated a therapeutically effective amount of an isolated human anti-CD38 antibody sufficient to treat the disease, the anti-CD38 antibody comprising a variable heavy (VH) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:3, a CDR2 having the amino acid sequence of SEQ ID NO:4, and a CDR3 having the amino acid sequence of SEQ ID NO:5 or a variant of those sequences with up to three amino acid changes, and a variable light (VL) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:6, a CDR2 having the amino acid sequence of SEQ ID NO:7, and a CDR3 having the amino acid sequence of SEQ ID NO:8 or a variant of those sequences with up to three amino acid changes, wherein the anti-CD38 antibody is administered in a dosage of between 45 and 1,800 milligrams.
[0016] In another aspect, the invention provides a method of treating a disease in a subject for which binding to CD38 is indicated, the method comprising the step of subcutaneously administering to a subject having a disease for which binding to CD38 is indicated a therapeutically effective amount of an isolated human anti-CD38 antibody sufficient to treat the disease, the anti-CD38 antibody comprising a VH chain region comprising CDR1 having the amino acid sequence of SEQ ID NO:3, a CDR2 having the amino acid sequence of SEQ ID NO:4, and a CDR3 having the amino acid sequence of SEQ ID NO:5 or a variant of those sequences with up to three amino acid substitutions, and a VL chain region comprising CDR1 having the amino acid sequence of SEQ ID NO:6, a CDR2 having the amino acid sequence of SEQ ID NO:7, and a CDR3 having the amino acid sequence of SEQ ID NO:8 or a variant of those sequences with up to three amino acid substitutions, the anti-CD38 antibody being administered in a dosage of between 45 and 1,800 milligrams.
[0017] In another aspect, the invention provides a method of treating a disease in a subject for which binding to CD38 is indicated, the method comprising the step of subcutaneously administering to a subject having a disease for which binding to CD38 is indicated a therapeutically effective amount of an isolated human anti-CD38 antibody sufficient to treat the disease, the anti-CD38 antibody comprising a VH chain region comprising CDR1 having the amino acid sequence of SEQ ID NO:3, a CDR2 having the amino acid sequence of SEQ ID NO:4, and a CDR3 having the amino acid sequence of SEQ ID NO:5, and a VL chain region comprising CDR1 having the amino acid sequence of SEQ ID NO:6, a CDR2 having the amino acid sequence of SEQ ID NO:7, and a CDR3 having the amino acid sequence of SEQ ID NO:8, and the anti-CD38 antibody is administered in a dosage of 45 to 1,800 milligrams.
[0018] In one embodiment, the anti-CD38 antibodies as described herein do not cause hemolytic anemia or thrombocytopenia.
[0019] In one aspect, administering an anti-CD38 antibody therapy reduces or eliminates less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, or less than 60% of one or more treatment-related adverse events (TRAEs) or treatment-emergent adverse events (TEAEs) of grade 3 or 4 selected from the group consisting of anemia, hemolytic anemia, neutropenia, thrombocytopenia, fatigue, infusion-related reactions (IRRs), leukopenia, and lymphopenia. 4%, 3%, 2%, or 1% incidence. TEAEs are adverse events observed or diagnosed up to about 30 days after the last dose of drug, regardless of cause. TEAEs may have any underlying cause related to disease or treatment that may be unrelated to anti-CD38 antibody or may be specifically related to anti-CD38 antibody. Advantageously, administering anti-CD38 antibody may result in less than 30% incidence of one or more treatment-emergent adverse events (TEAEs) of grade 3 or 4 selected from the group consisting of anemia, hemolytic anemia, thrombocytopenia, fatigue, infusion-related reaction (IRR), leukopenia, and lymphopenia.
[0020] In one aspect, administering an anti-CD38 antibody therapy results in less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% incidence of one or more treatment-related adverse events (TRAEs) of grade 3 or 4 selected from the group consisting of anemia, hemolytic anemia, neutropenia, thrombocytopenia, fatigue, infusion-related reactions (IRR), leukopenia, and lymphopenia. A TRAE is an adverse event for which the treating physician believes there may be a causal relationship between the drug used for treatment and the adverse event. Thus, a TRAE is considered to be specifically related to an anti-CD38 antibody. Preferably, administering the anti-CD38 antibody may result in a less than 30% incidence of one or more grade 3 or 4 TRAEs selected from the group consisting of anemia, hemolytic anemia, thrombocytopenia, fatigue, infusion-related reactions (IRR), leukopenia, and lymphopenia.
[0021] In one aspect, administering an anti-CD38 antibody therapy results in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% depletion of RBCs.
[0022] In one aspect, administering an anti-CD38 antibody therapy results in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% depletion of platelets.
[0023] In one aspect, the disease is an autoimmune disease or cancer.
[0024] In one aspect, the autoimmune disease is selected from the group consisting of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), ulcerative colitis (UC), systemic light chain amyloidosis, and graft-versus-host disease.
[0025] In one aspect, the hematological cancer is selected from the group consisting of multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myelogenous leukemia, B-cell lymphoma, and Burkitt's lymphoma.
[0026] In one aspect, the hematological cancer is multiple myeloma.
[0027] In another aspect, the autoimmune disease is systemic light chain amyloidosis.
[0028] In one aspect, the VH chain region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 9 and the VL chain region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 10. Suitably, the VH chain region may comprise an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 9 and the VL chain region comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 10. Suitably, the VH chain region may comprise an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9 and the VL chain region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 10. Suitably, the VH chain region may comprise an amino acid sequence having at least 95% sequence identity to SEQ ID NO:9 and the VL chain region comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:10. Suitably, the VH chain region may comprise an amino acid sequence having at least 97% sequence identity to SEQ ID NO:9 and the VL chain region comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO:10. Suitably, the VH chain region may comprise an amino acid sequence having at least 99% sequence identity to SEQ ID NO:9 and the VL chain region comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO:10.
[0029] Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 80% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 80% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 85% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 85% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 90% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 90% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 95% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 95% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 97% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 97% sequence identity to SEQ ID NO:10.Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 99% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 99% sequence identity to SEQ ID NO:10.
[0030] In one embodiment, the VH chain region has the amino acid sequence of SEQ ID NO: 9 or a variant thereof having up to three amino acid substitutions, and the VL chain region has the amino acid sequence of SEQ ID NO: 10 or a variant thereof having up to three amino acid substitutions.
[0031] In one embodiment, the VH chain region has the amino acid sequence of SEQ ID NO:9 and the VL chain region has the amino acid sequence of SEQ ID NO:10.
[0032] In one aspect, the VH chain region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 12.
[0033] Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 80% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 80% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 85% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 85% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 90% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 90% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 95% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 95% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of which may have at least 97% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of which may have at least 97% sequence identity to SEQ ID NO:12.Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 99% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 99% sequence identity to SEQ ID NO:12.
[0034] In one embodiment, the anti-CD38 antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 11, or a variant thereof having up to three amino acid substitutions, and a light chain amino acid sequence of SEQ ID NO: 12, or a variant thereof having up to three amino acid substitutions.
[0035] In one embodiment, the anti-CD38 antibody comprises the heavy chain amino acid sequence of SEQ ID NO:11 and the light chain amino acid sequence of SEQ ID NO:12.
[0036] In one embodiment, the therapeutically effective amount is a dosage of 45 to 1,800 milligrams. Preferably, the therapeutically effective amount may be a dosage of 45 to 1,200 milligrams. Preferably, the therapeutically effective amount may be a dosage of 45 to 600 milligrams. Preferably, the therapeutically effective amount may be a dosage of 45 to 135 milligrams. Preferably, the therapeutically effective amount may be a dosage of 135 to 1,800 milligrams. Preferably, the therapeutically effective amount may be a dosage of 135 to 1,200 milligrams. Preferably, the therapeutically effective amount may be a dosage of 135 to 600 milligrams. The therapeutically effective amount may be a dosage of 600 to 1,800 milligrams. Preferably, the therapeutically effective amount may be a dosage of 600 to 1,200 milligrams. Preferably, the therapeutically effective amount may be a dosage of 1,200 to 1,800 milligrams.
[0037] In one embodiment, the human anti-CD38 antibody is administered in the form of a pharma- ceutically acceptable composition.
[0038] In another aspect, the invention provides a method of treating a hematological cancer in a subject, the method comprising the step of subcutaneously administering to a subject having a hematological cancer a therapeutically effective amount of an isolated human anti-CD38 antibody sufficient to treat the hematological cancer, the anti-CD38 antibody comprising a VH chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:3, a CDR2 having the amino acid sequence of SEQ ID NO:4, and a CDR3 having the amino acid sequence of SEQ ID NO:5 or a variant of those sequences with up to three amino acid changes, and a VL chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:6, a CDR2 having the amino acid sequence of SEQ ID NO:7, and a CDR3 having the amino acid sequence of SEQ ID NO:8 or a variant of those sequences with up to three amino acid changes, wherein the antibody is administered in a dosage of between 45 and 1,800 milligrams.
[0039] In another aspect, the invention provides a method of treating a hematological cancer in a subject, the method comprising the step of subcutaneously administering to a subject having a hematological cancer a therapeutically effective amount of an isolated human anti-CD38 antibody sufficient to treat the hematological cancer, the anti-CD38 antibody comprising a VH chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:3, a CDR2 having the amino acid sequence of SEQ ID NO:4, and a CDR3 having the amino acid sequence of SEQ ID NO:5 or a variant of those sequences with up to three amino acid substitutions, and a VL chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:6, a CDR2 having the amino acid sequence of SEQ ID NO:7, and a CDR3 having the amino acid sequence of SEQ ID NO:8 or a variant of those sequences with up to three amino acid substitutions, wherein the anti-CD38 antibody is administered in a dosage of between 45 and 1,800 milligrams.
[0040] In another aspect, the invention provides a method of treating a hematological cancer in a subject, the method comprising the step of subcutaneously administering to a subject having a hematological cancer a therapeutically effective amount of an isolated human anti-CD38 antibody sufficient to treat the hematological cancer, the anti-CD38 antibody comprising a VH chain region comprising CDR1 having the amino acid sequence of SEQ ID NO:3, a CDR2 having the amino acid sequence of SEQ ID NO:4, and a CDR3 having the amino acid sequence of SEQ ID NO:5, and a VL chain region comprising CDR1 having the amino acid sequence of SEQ ID NO:6, a CDR2 having the amino acid sequence of SEQ ID NO:7, and a CDR3 having the amino acid sequence of SEQ ID NO:8, wherein the anti-CD38 antibody is administered in a dosage of 45 to 1,800 milligrams.
[0041] In one embodiment, the anti-CD38 antibody does not cause hemolytic anemia or thrombocytopenia.
[0042] In one aspect, administering the anti-CD38 antibody results in less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 4%, less than 3%, less than 3%, or less than 1% incidence of one or more treatment-related adverse events (TRAEs) or TEAEs of grade 3 or 4 selected from the group consisting of anemia, including hemolytic anemia, thrombocytopenia, fatigue, infusion-related reactions (IRR), leukopenia, and lymphopenia. Suitably, administering the anti-CD38 antibody may result in less than 30% incidence of one or more treatment-related adverse events or TEAEs of grade 3 or 4 selected from the group consisting of anemia, including hemolytic anemia, thrombocytopenia, fatigue, infusion-related reactions (IRR), leukopenia, and lymphopenia.
[0043] In one embodiment, administering an anti-CD38 antibody results in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% depletion of RBCs. results.
[0044] In one aspect, administering the anti-CD38 antibody results in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% depletion of platelets.
[0045] In one aspect, the hematological cancer is selected from the group consisting of multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myelogenous leukemia, B-cell lymphoma, and Burkitt's lymphoma.
[0046] In one aspect, the hematological cancer is multiple myeloma.
[0047] In one aspect, the VH chain region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 9 and the VL chain region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 10. Suitably, the VH chain region may comprise an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 9 and the VL chain region comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 10. Suitably, the VH chain region may comprise an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9 and the VL chain region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 10. Suitably, the VH chain region may comprise an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 9 and the VL chain region comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 10. Suitably, the VH chain region may comprise an amino acid sequence having at least 97% sequence identity to SEQ ID NO:9, and the VL chain region comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO:10. Suitably, the VH chain region may comprise an amino acid sequence having at least 99% sequence identity to SEQ ID NO:9, and the VL chain region comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO:10.
[0048] Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 80% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 80% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 85% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 85% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 90% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 90% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 95% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 95% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, with the remainder of the sequence having at least 97% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, with the remainder of the VL sequence having at least 97% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, with the remainder of the VL sequence having at least 97% sequence identity to SEQ ID NO:10. 3, SEQ ID NO:4, and SEQ ID NO:5, with the remainder of the sequence having at least 99% sequence identity to SEQ ID NO:9, and the VL chain may comprise CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, with the remainder of the VL sequence having at least 99% sequence identity to SEQ ID NO:10.
[0049] In one embodiment, the VH chain region has the amino acid sequence of SEQ ID NO: 9 or a variant thereof having up to three amino acid substitutions, and the VL chain region has the amino acid sequence of SEQ ID NO: 10 or a variant thereof having up to three amino acid substitutions.
[0050] In one embodiment, the VH chain region has the amino acid sequence of SEQ ID NO:9 and the VL chain region has the amino acid sequence of SEQ ID NO:10.
[0051] In one aspect, the VH chain region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 11, and the VL chain region comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 11, and the VL chain region comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 12.
[0052] Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 80% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 80% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 85% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 85% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 90% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 90% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 95% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 95% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, with the remainder of the sequence having at least 97% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, with the remainder of the VL sequence having at least 97% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, with the remainder of the VL sequence having at least 97% sequence identity to SEQ ID NO:12. , the VL chain may comprise CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and the remainder of the sequence may have at least 99% sequence identity to SEQ ID NO:11, and the VL chain may comprise CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, and the remainder of the VL sequence may have at least 99% sequence identity to SEQ ID NO:12.
[0053] In one embodiment, the VH chain region has the amino acid sequence of SEQ ID NO: 11 or a variant thereof with up to three amino acid substitutions, and the VL chain region has the amino acid sequence of SEQ ID NO: 12 or a variant thereof with up to three amino acid substitutions.
[0054] In one embodiment, the anti-CD38 antibody comprises the heavy chain amino acid sequence of SEQ ID NO:11 and the light chain amino acid sequence of SEQ ID NO:12.
[0055] In one embodiment, the therapeutically effective amount is a dosage of 45 to 1,800 milligrams. Preferably, the therapeutically effective amount may be a dosage of 45 to 1,200 milligrams. Preferably, the therapeutically effective amount may be a dosage of 45 to 600 milligrams. Preferably, the therapeutically effective amount may be a dosage of 45 to 135 milligrams. Preferably, the therapeutically effective amount may be a dosage of 135 to 1,800 milligrams. Preferably, the therapeutically effective amount may be a dosage of 135 to 1,200 milligrams. Preferably, the therapeutically effective amount may be a dosage of 135 to 600 milligrams. Preferably, the therapeutically effective amount may be a dosage of 600 to 1,800 milligrams. Preferably, the therapeutically effective amount may be a dosage of 600 to 1,200 milligrams. Suitably, the therapeutically effective amount may be a dosage of 1,200 to 1,800 milligrams.
[0056] In one embodiment, the human anti-CD38 antibody is administered in the form of a pharma- ceutically acceptable composition. Suitably, the pharma-ceutically acceptable composition may be suitable for subcutaneous administration.
[0057] In another aspect, the present invention provides a unit dosage form comprising an isolated antibody comprising an amino acid sequence of a heavy chain variable region having at least 80% sequence identity to SEQ ID NO:9 and an amino acid sequence of a light chain variable region having at least 80% sequence identity to SEQ ID NO:10, wherein the isolated antibody binds to CD38, and the unit dosage form is formulated for subcutaneous administration at a dosage of 45 to 1,800 milligrams of the antibody. Suitably, the VH chain region may comprise an amino acid sequence having at least 85% sequence identity to SEQ ID NO:9, and the VL chain region comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO:10. Suitably, the VH chain region may comprise an amino acid sequence having at least 90% sequence identity to SEQ ID NO:9, and the VL chain region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:10. Suitably, the VH chain region may comprise an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 9, and the VL chain region comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 10. Suitably, the VH chain region may comprise an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 9, and the VL chain region comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 10. Suitably, the VH chain region may comprise an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 9, and the VL chain region comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 10.
[0058] Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, with the remainder of the sequence having at least 85% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, with the remainder of the VL sequence having at least 85% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, with the remainder of the VL sequence having at least 85% sequence identity to SEQ ID NO:10. The VH chain may comprise CDR sequences as defined by SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, the remainder of the sequence having at least 85% sequence identity to SEQ ID NO: 9, and the VL chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, the remainder of the VL sequence having at least 85% sequence identity to SEQ ID NO: 10. Suitably, the VH chain may comprise CDR sequences as defined by SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, the remainder of the sequence having at least 90% sequence identity to SEQ ID NO: 9, and the VL chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, the remainder of the VL sequence having at least 90% sequence identity to SEQ ID NO: 10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 95% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 95% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 97% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 97% sequence identity to SEQ ID NO:10. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 99% sequence identity to SEQ ID NO:9, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 99% sequence identity to SEQ ID NO:10.
[0059] Suitably, the present invention may provide a unit dosage form comprising an isolated antibody comprising the amino acid sequence of a heavy chain variable region of SEQ ID NO: 9 or a variant thereof having up to three amino acid substitutions and the amino acid sequence of a light chain variable region of SEQ ID NO: 10 or a variant thereof having up to three amino acid substitutions, wherein the isolated antibody binds to CD38, and the unit dosage form is formulated for subcutaneous administration at a dosage of 45 to 1,800 milligrams of the antibody.
[0060] In another aspect, the invention provides a unit dosage form comprising an isolated antibody comprising the amino acid sequence of a heavy chain variable region of SEQ ID NO: 9 and the amino acid sequence of a light chain variable region of SEQ ID NO: 10, wherein the isolated antibody binds to CD38 and does not significantly bind to human red blood cells, wherein the unit dosage form is formulated for subcutaneous administration at a dosage of between 45 and 1,800 milligrams of the antibody.
[0061] In one aspect, the heavy chain comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 11 and the light chain comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 11 and the VL chain region comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 11, and the VL chain region may comprise an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise CDR sequences as defined by SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, with the remainder of the sequence having at least 80% sequence identity to SEQ ID NO: 11, and the VL chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8. and the remainder of the VL sequence may have at least 85% sequence identity to SEQ ID NO: 11. Suitably, the VH chain may comprise CDR sequences as defined by SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, the remainder of the sequence may have at least 85% sequence identity to SEQ ID NO: 12, and the VL chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, the remainder of the VL sequence may have at least 85% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise CDR sequences as defined by SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, the remainder of the sequence may have at least 90% sequence identity to SEQ ID NO: 11, and the VL chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, the remainder of the VL sequence may have at least 90% sequence identity to SEQ ID NO: 12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 95% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 95% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 97% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 97% sequence identity to SEQ ID NO:12. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 99% sequence identity to SEQ ID NO:11, and the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, the remainder of the VL sequence having at least 99% sequence identity to SEQ ID NO:12.
[0062] Suitably, the heavy chain may comprise the amino acid sequence of SEQ ID NO: 11 or a variant thereof with up to three amino acid substitutions, and the light chain may comprise the amino acid sequence of SEQ ID NO: 12 with up to three amino acid substitutions.
[0063] In one embodiment, the heavy chain may comprise the amino acid sequence of SEQ ID NO:11 and the light chain may comprise the amino acid sequence of SEQ ID NO:12.
[0064] In one aspect, the unit dosage form is formulated for subcutaneous administration of the antibody in the treatment of a hematological cancer selected from the group consisting of multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myelogenous leukemia, B-cell lymphoma, and Burkitt's lymphoma.
[0065] In one aspect, the hematological cancer is multiple myeloma.
[0066] In one embodiment, the anti-CD38 antibody does not cause hemolytic anemia or thrombocytopenia.
[0067] In one embodiment, the anti-CD38 antibody results in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% depletion of RBCs.
[0068] In one aspect, the anti-CD38 antibody results in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% depletion of platelets.
[0069] In one aspect, a human anti-CD38 antibody for use in therapy is provided, which does not cause significant levels of red blood cell and / or platelet depletion following administration. Suitably, the human anti-CD38 antibody may be administered subcutaneously. Suitably, the antibody may be administered intracellularly at a concentration of 45 to 1,800 μg / mL. It may be administered in doses as low as 10 mg / kg.
[0070] In one aspect, a human anti-CD38 antibody for use in therapy is provided, the antibody not causing significant levels of red blood cell and / or platelet depletion following administration, the human anti-CD38 antibody being administered subcutaneously at a dosage of between 45 and 1,800 milligrams. Suitably, the human anti-CD38 antibody not causing significant levels of red blood cell and / or platelet depletion following administration may be an anti-CD38 antibody as defined herein.
[0071] In one aspect, a unit dosage form is provided comprising an isolated antibody that does not cause significant levels of red blood cell and / or platelet depletion following administration, the isolated antibody binds to CD38 and does not bind to human red blood cells, the unit dosage form being formulated for subcutaneous administration at a dosage of between 45 and 1,800 milligrams of the antibody.
[0072] In one aspect there is provided a human anti-CD38 antibody as defined herein for use in therapy, wherein the human anti-CD38 antibody is formulated for subcutaneous administration. Suitably, the human anti-CD38 antibody is administered subcutaneously.
[0073] In one aspect there is provided a human anti-CD38 antibody as defined herein for use in the treatment of a disease in which binding to CD38 is indicated, wherein the human anti-CD38 antibody is formulated for subcutaneous administration. Suitably the human anti-CD38 antibody is administered subcutaneously.
[0074] In many embodiments, the dosage of anti-CD38 antibody administered as described herein is a weekly dosage.
[0075] In one aspect there is provided a human anti-CD38 antibody as defined herein for use in therapy, wherein the human anti-CD38 antibody is formulated for subcutaneous administration. Suitably, the human anti-CD38 antibody is administered subcutaneously.
[0076] Suitably, the human anti-CD38 antibody may be administered in a dosage range of 45 to 1,800 milligrams of antibody. Suitably, the human anti-CD38 antibody may be formulated for subcutaneous administration. Suitably, the human anti-CD38 antibody may be formulated for subcutaneous administration and administered in a dosage range of 45 to 1,800 milligrams of antibody.
[0077] In one aspect there is provided a human anti-CD38 antibody as defined herein for use in the treatment of cancer. Suitably the cancer may be a haematological cancer.
[0078] In one aspect, there is provided a human anti-CD38 antibody as defined herein for use in the treatment of haematological cancer, wherein the human anti-CD38 antibody is formulated for subcutaneous administration. Suitably, the human anti-CD38 antibody may be administered subcutaneously.
[0079] Suitably, the human anti-CD38 antibody may be administered in a dosage range of 45 to 1,800 milligrams of antibody. Suitably, the human anti-CD38 antibody may be formulated for subcutaneous administration. Suitably, the human anti-CD38 antibody may be formulated for subcutaneous administration and administered in a dosage range of 45 to 1,800 milligrams of antibody.
[0080] In one aspect there is provided a human anti-CD38 antibody as defined herein for use in the treatment of hematological cancer, wherein the human anti-CD38 antibody is formulated for subcutaneous administration, and wherein the human anti-CD38 antibody is administered at a dosage in the range of 45 to 1,800 milligrams of antibody. Suitably, the human anti-CD38 antibody may be administered subcutaneously.
[0081] Preferably, the blood cancer may be multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, B-cell lymphoma, or Burkitt's lymphoma. Preferably, the blood cancer may be multiple myeloma.
[0082] In one aspect there is provided a human anti-CD38 antibody as defined herein for use in the treatment of an autoimmune disease.
[0083] In one aspect, there is provided a human anti-CD38 antibody as defined herein for use in the treatment of an autoimmune disease, wherein the human anti-CD38 antibody is formulated for subcutaneous administration. Suitably, the human anti-CD38 antibody may be administered subcutaneously.
[0084] Suitably, the human anti-CD38 antibody may be administered in a dosage range of 45 to 1,800 milligrams of antibody. Suitably, the human anti-CD38 antibody may be formulated for subcutaneous administration. Suitably, the human anti-CD38 antibody may be formulated for subcutaneous administration and administered in a dosage range of 45 to 1,800 milligrams of antibody.
[0085] Suitably, the autoimmune disease may be systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), ulcerative colitis, systemic light chain amyloidosis, or graft-versus-host disease.
[0086] In one aspect, a pharmaceutical composition is provided comprising an isolated human anti-CD38 antibody as defined herein.
[0087] In one aspect, a pharmaceutical composition is provided comprising a unit dosage form according to the invention.
[0088] In one aspect there is provided a pharmaceutical composition according to the invention for use in therapy.
[0089] In one aspect there is provided a pharmaceutical composition according to the invention for use in the treatment of a disease in which binding to CD38 is indicated.
[0090] In one aspect, the pharmaceutical composition according to the present invention is provided for use in the treatment of autoimmune disease.Preferably, the autoimmune disease may be systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), ulcerative colitis (UC), systemic light chain amyloidosis, or graft-versus-host disease.Preferably, the autoimmune disease may be systemic lupus erythematosus (SLE).Preferably, the autoimmune disease may be rheumatoid arthritis (RA).Preferably, the autoimmune disease may be inflammatory bowel disease (IBD).Preferably, the autoimmune disease may be ulcerative colitis (UC).Preferably, the autoimmune disease may be graft-versus-host disease.
[0091] In another aspect, there is provided a pharmaceutical composition according to the present invention for use in the treatment of cancer. Preferably, the cancer may be a blood cancer. Preferably, the blood cancer may be multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myelogenous leukemia, B cell lymphoma, or Burkitt's lymphoma. Preferably, the blood cancer may be multiple myeloma. Preferably, the blood cancer may be chronic lymphoblastic leukemia. Preferably, the blood cancer may be chronic lymphocytic leukemia. Preferably, the blood cancer may be plasma cell leukemia. Preferably, the blood cancer may be acute myeloid leukemia. Preferably, the blood cancer may be chronic myeloid leukemia. Preferably, the blood cancer may be B cell lymphoma. Preferably, the blood cancer may be Burkitt's lymphoma.
[0092] In one aspect, an isolated compound as defined herein is used for the manufacture of a medicament for the treatment of a disease. Use of the human anti-CD38 antibody is provided.
[0093] In another aspect, there is provided the use of a unit dosage form according to the invention for the manufacture of a medicament for the treatment of a disease.
[0094] Suitably, the disease may be one in which binding to CD38 is indicated.
[0095] Suitably, the disease may be an autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), ulcerative colitis (UC), systemic light chain amyloidosis, or graft-versus-host disease.
[0096] Preferably, the disease may be cancer. Preferably, the cancer may be a blood cancer such as multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myelogenous leukemia, B-cell lymphoma, or Burkitt's lymphoma.
[0097] Suitably, the medicament may be formulated for subcutaneous administration.
[0098] Suitably, the medicament may be formulated to provide a dosage of between 45 and 1,800 milligrams of antibody.
[0099] Suitably, the medicament is formulated for subcutaneous administration and may be in a dosage of between 45 and 1,800 milligrams of antibody.
[0100] These and other embodiments, features and potential advantages will become apparent with reference to the following description and drawings.
[0101] The objects and features of the present invention may be better understood with reference to the drawings described below. [Brief description of the drawings]
[0102] [Figure 1] A table of antibodies used for flow cytometry analysis in PD studies is shown. [Diagram 2] PK data for the SC dosing group are shown. Anti-drug antibodies (ADA) were detected by a validated qualitative electrochemiluminescence (ECL) assay. The incidence increased over time and affected PK when it reached a certain threshold titer of approximately 1000 (approximately log(7)). [Diagram 3]Figure 2 shows the PK data and model for AB79 in cynomolgus monkeys (cyno). Panels A and B show the raw PK data from eight monkey studies: (Panel A) the first 7 days after the first dose; (Panel B) the entire observation period. Doses are color coded and SC data has been omitted (Figure 2). Panel C illustrates the final PK model structure with target-mediated pharmacokinetics (TMDD) marked with a blue box. VC represents the volume of the central compartment where AB79 concentrations are observed (marked with concentration). VP represents the volume of the peripheral compartment. R represents the compartment of antibody bound and unbound receptor CD38. KSYN and KDEG represent the formation and degradation rate constants of the receptor, and KINT represents the internalization rate constant (complex elimination rate constant). KSS is the steady-state constant defined as KSS = (KOFF + KINT) / KON, where KOFF is the dissociation and KON is the association rate constant. Panels D-F show the overlay of the linear two-compartment model predictions (median, 95% prediction interval) without the TMDD component and the observed data (study 8) for the three lowest doses. Note that the time scales between panels D, E, and F are different. [Figure 4] 1 shows the effect of AB79 treatment on RBCs two days post-dosing and total lymphocyte counts on the first day post-dosing in Study 7. [Diagram 5] The effect of ADA in a 13-week toxicology study is shown. The evaluation refers to the final population PK model (Figure 1, Table 4). The following goodness-of-fit (GOF) plots stratified by dose and route of administration are presented (Keizer et al. (2013) CPT Pharmacometrics Syst. Pharmacol. 2:e50): (1) Conditional Weighted Residuals (CWRES) vs. time, (2) Observed concentration vs. population model prediction, (3) CWRES vs. population model prediction, and (4) Observed concentration vs. individual model prediction. [Figure 6A] GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 6B]GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 6C] GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 6D] GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 6E] GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 6F] GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 6G] GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 6H] GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 6I] GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 6J] GOF plots for the final population PK model stratified by dose and route of administration (IV-red, SC-blue). [Figure 7]Comparison of CD38 expression on the surface of human and monkey NK cells, B cells, and T cells. Flow cytometry measurements were standardized and signals are reported in molecules of equivalent soluble fluorescence (MOEF). Human and monkey blood lymphocytes bind similar levels of AB79. Direct comparison of CD38 expression levels on monkey NK cells (CD3-, CD159a+), B cells (CD3-, CD20+), and T cells (CD3+), as well as human NK cells (CD3-, CD16 / CD56+), B cells (CD3-, CD19+), and T cells (CD3+) was assessed by flow cytometry. Median fluorescence intensity (MFI) of AB79 staining for each cell population was converted to MOEF units using a standard curve generated with Rainbow Beads (Spherotech, Lake Forest, IL). Data shown are from three individuals of each species and show MOEF±SD for each cell type. Differences in CD38 expression exist among blood lymphocytes, with the highest level of AB79 binding (MOEF) being NK cells>B cells>T cells. The pattern of AB79 binding is similar in blood cells from monkeys, but the level of AB79 binding / CD38 expression is lower. [Figure 8] Inter- and intra-individual variability of T cell, B cell, and NK cell count data from placebo-treated animals is shown. [Figure 9] Pre-dose NK, B, and T cell counts (cells per μL) are shown stratified by study (top row) or gender (bottom row). [Figure 10]AB79-dependent NK cell, B cell, and T cell depletion is shown. The graphs presented focus on the changes that occurred within the first 7 days after treatment with the first dose of AB79. It was thereby possible to pool data from single-dose and multiple-dose studies with weekly or biweekly dosing schedules. Graphs A-C show the individual minimum cell counts (i.e., maximum PD effect) of NK cells, the individual cell counts 7 days after the first dose, as well as the average cell depletion profile and PK-PD model structure per dose, respectively. Graphs E-F show the same information for B cells, and graphs G-I show the same information for T cells. [Figure 11] Simulated human PK, and NK cell, B cell, and T cell depletion profiles of AB79 are shown. Based on the scaled monkey PK and PK-PD models, five PK and cell depletion profiles of single IV and SC dosing were simulated (0.0003-1 mg / kg). The plots on the left show data after IV dosing, and the plots on the right show data after SC dosing. The first row of plots displays the PK profiles. The lower limit of quantification (LLOQ) of 0.05 μg / mL is indicated by the horizontal dashed line. The PK of the lowest dose was completely superimposed on the noise, and only at the dose of 0.03 mg / kg did PK reach levels above the LLOQ. [Figure 12] The design for a single ascending dose study of AB79 in healthy volunteers (toxicity study) is shown. A total of 6 IV and 4 SC cohorts in 74 subjects were randomized to receive a single dose of AB79. Extensive blinded safety, PK and PD data were reviewed after each cohort and prior to dose escalation. Stopping criteria included target cell depletion to avoid potential immunosuppression in healthy volunteers. Each subject was followed for 92 days after dosing. [Figure 13A] GOF plots for the PK-PD model stratified by route of administration (IV-red, SC-blue) are shown (NK cells). [Figure 13B] GOF plots for the PK-PD model stratified by route of administration (IV-red, SC-blue) are shown (B cells). [Figure 13C] GOF plots for the PK-PD model stratified by route of administration (IV-red, SC-blue) are shown (T cells). [Figure 14] Figure 2 shows that AB79 mediates cell depletion by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Comparison of CD38 receptor numbers and susceptibility to ADCC and CDC in human B-lineage cell lines. Cell lines with increased CD38 expression were more susceptible to ADCC. No ADCC was observed in a human lymphoblastoid cell line (MV-4-11) that does not express CD38, or in a Chinese hamster ovary cell line transfected with CD157, a molecule closely related to CD38 (data not shown). EC50, 50% effective concentration; nd, not done; SD, standard deviation. [Figure 15] Figure 1 shows that AB79 mediates monkey lymphocyte depletion. AB79 dose-dependently depleted blood NK cells>B cells>T cells after a single IV dose of AB79 in female cynomolgus monkeys (n=4 / dose group) as quantified by flow cytometry with Flow-Count™ Fluorospheres (Beckman-Coulter). Samples were collected pre-treatment (week -1), day 1: pre-dose, 15 min, 30 min, 1 h, 4 h, 8 h, 24 h, 48 h, 96 h, and 168 h post-dose, day 10, day 15, day 22, day 29, day 36, day 43, day 50, and day 57. For clarity, only 2 weeks of data are shown. Mean cell count values were calculated at each time point and used to calculate % of baseline counts. [Figure 16]Figure 1 shows that human tetanus toxoid (TTd) recall responses are reduced by AB79 treatment. CB17 / SCID mice were treated with anti-asialo GM1 to eliminate NK cells and then given 25 x 106 human peripheral blood lymphocytes. After 7-10 days, serum samples were collected for assessment of human Ig, and Ig levels were the basis for randomization. Mice were given TTd to induce a recall response and treated with the indicated antibodies twice / week for 10 days. Three days after the last treatment, serum was collected and analyzed for anti-TTd antibodies. AB79 dose-dependently suppressed the TTd recall response. AB79 reduced the recall response to an extent similar to that of Rituxan (Rtx) (isotype (iso), Rtx, and AB79, all at 10 mg / kg. [Figure 17] AB79 does not induce cytokine induction. AB79 (soluble) did not increase IL-6 levels after 24 hours of incubation in PBMCs collected from four different subjects. In comparison, the IgG1 isotype control PHA (positive control) increased cytokine levels in all subjects, demonstrating that the cells have the ability to produce IL-6. Similar results were seen in PBMCs stimulated for 48 hours, as well as when IL-2, IL-4, IL-10, GM-CSF, IFNγ, and TNFα were tested (data not shown). [Figure 18A] FIG. 18B shows the dry binding, wet binding, and solubility experimental setup (modified from Stebbings et al. (2007) J. Immunol. 179:3325-3331). [Figure 18B]This shows that AB79 has no agonist activity. AB79 is highly concentrated when it is added to the wells in solution and the liquid is evaporated (dry binding), as opposed to AB79 being bound to the wells in solution (wet binding) or added directly to PBMCs (soluble). AB79 did not stimulate IL-6 or IL-2, IL-4, IL-8, IL-10, GM-CSF, IFNγ, or TNFα after 24 hours under any of the conditions tested. IL-8 is constitutively produced by PBMCs and was not altered by any of the treatments (data not shown). [Figure 19] AB79 binding to cynomolgus monkey CD45+ lymphocytes is shown. AB79 binding to CD45+ lymphocytes in unlysed cynomolgus monkey whole blood. CD45+ lymphocytes were gated and then assessed for binding of AB79 (black histogram) or isotype control (red histogram). AB79 binding was detected on a subset of lymphocytes, as illustrated by the percentage of cells to the right of the red dashed line. Little to no binding of isotype control to lymphocytes is observed. [Figure 20A] The mean observed Cmax and pre-dose trough (ng / ml) levels (Cycle 1 and Cycle 2) are shown. Cmax (ng / ml) of Ab79 is shown. [Figure 20B] The mean observed Cmax and pre-dose trough (ng / ml) levels (Cycle 1 and Cycle 2) are shown. The concentration of Ab79 (ng / ml) is shown. [Figure 21] 1 shows that subcutaneously administered Ab79 reduced blood plasmablast levels in a dose-dependent manner. [Figure 22] 1 shows that subcutaneously administered Ab79 reduced the levels of plasmablasts in bone marrow aspirates in a dose-dependent manner. [Figure 23] 1 shows that subcutaneously administered Ab79 reduced the levels of plasma cells in bone marrow aspirates in a dose-dependent manner. [Figure 24] NK cell levels in peripheral blood of healthy subjects after a single SC administration of AB79. SC, subcutaneous. [Diagram 25]1 shows levels of plasmablasts, monocytes, B cells, T cells, and NK cells in peripheral blood from healthy subjects following a single injection of placebo control, 0.1, 0.3, or 0.6 mg kg −1 of AB79 (SC).
number
number
number
number
number
number
number
[0103] The present invention relates to a method for treating CD-38-associated diseases by subcutaneous administration of an anti-CD38 antibody.
[0104] In the vasculature of patients with active disease, there are approximately 36 times more CD38 molecules expressed on RBCs than on myeloma cells. Therefore, for example, the off-target expression of CD38 may need to be saturated before unbound antibodies can pass into the bone marrow and saturate the CD38 expressed on myeloma cells. This may explain why other anti-CD38 antibodies in the art, such as daratumumab and isatuximab, which bind strongly to RBCs and platelets, may require high systemic doses to achieve efficacy.
[0105] AB79, daratumumab, isatuximab, and MOR202 are IgG1s that kill tumors primarily by antibody-dependent cellular cytotoxicity (ADCC). This mechanism requires effector cells, such as NK cells, to bind to antibodies on target cells, form lytic synapses, and secrete cytotoxic substances in a concentrated manner. The frequency of these effector cells in blood is orders of magnitude lower than that of RBCs and platelets. For example, the ratio of RBCs to NK cells in blood is 20,000:1. As a result, the effector activity of daratumumab, isatuximab, and MOR202 is diverted away from tumors because effector cells primarily bind to anti-CD-38 antibodies bound to RBCs and platelets, preventing the formation of lytic synapses with tumors, which results in low ADCC efficiency.
[0106] Treatment of patients with anti-CD38 antibodies that bind to RBCs and platelets can result in life-threatening side effects. For example, in one study, treatment of relapsed or refractory multiple myeloma with MOR202 resulted in several serious treatment-related adverse events or TEAEs (see, e.g., Raab et al. (2015) Blood 126:3035). The most common TEAEs of any grade were anemia (15 patients, 34%), fatigue (14 patients, 32%), infusion-related reactions (IRR) and leukopenia (13 patients, 30%), lymphopenia and nausea (11 patients, 25%). Grade ≥3 TEAEs were reported in 28 patients (64%), the most common of which included lymphopenia (8 patients, 18%), leukopenia (5 patients, 11%), and nausea (11 patients, 25%). %), and hypertension (4 patients, 9%). IRRs occurred primarily during the first infusion and were all grade 1-2 except for one patient (grade 3). Infections were commonly reported (26 patients, 59%), but the majority of cases were not considered treatment-related. MOR202 is in clinical use only via IV infusion.
[0107] Other Morphosys antibodies targeting CD38 are known (see, for example, WO2006 / 125640, which discloses four human antibodies, MOR03077, MOR03079, MOR03080, and MOR03100, and two murine antibodies, OKT10 and IB4). These prior art antibodies are inferior to the antibodies for use according to the present invention (e.g., AB79) for a variety of reasons. MOR03080 binds to human CD38 and cynomolgus monkey CD38, but with low affinity to human CD38 (Biacore K D = 27.5 nm). OKT10 binds to human CD38 and cynomolgus monkey CD38, but has low / moderate affinity for human CD38 (Biacore K D =8.28 nm). MOR03079 has high affinity (Biacore K D= 2.4 nm) binds to human CD38 but not to cynomolgus monkey CD38. MOR03100 and MOR03077 bind with moderate or low affinity (Biacore K D = 10 nm and 56 nm, respectively). In comparison, antibodies for use according to the invention (e.g., AB79) bind to human CD38 with high affinity (Biacore K D = 5.4 nm) to bind to human and cynomolgus CD38. Moreover, the prior art antibodies have poor ADCC as well as CDC activity.
[0108] The advantage of more efficient ADCC is that anti-CD38 therapeutics can be delivered as low volume injections. If an antibody for use according to the invention (e.g., AB79) is formulated at a concentration of 100 mg / mL, an effective dose for an 80 kg myeloma patient can be administered as a single subcutaneous injection of <1.0 mL. In contrast, an effective dose of daratumumab or isatuximab delivered to this patient in a comparable form (i.e., 100 mg / mL) would require administration of 12.8 mL or 8-16 mL, respectively.
[0109] The anti-CD38 methods and unit dosage amounts herein provide for subcutaneous administration of a therapeutically effective dose of an anti-CD38 antibody, thereby providing unexpected benefits while avoiding the side effects, inconvenience, and expense of administering high-dose systemic anti-CD38 antibody therapy.
[0110] The present invention provides methods and unit dosage forms for subcutaneously administering a therapeutically effective amount of an isolated anti-CD38 antibody to a patient in need thereof to treat a disease in which binding to CD38 is indicated, including hematological cancers. In some embodiments, the antibody for subcutaneous administration comprises a heavy chain variable region comprising SEQ ID NO: 9 (or a sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity thereto) and a light chain variable region comprising SEQ ID NO: 10 (or a sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity thereto). The anti-CD38 antibodies provided herein can be therapeutically effective when administered by subcutaneous administration.
[0111] Another advantage of the anti-CD38 antibodies of the invention is that, unlike some other anti-CD38 antibodies in the clinical setting, the anti-CD38 antibodies of the invention (e.g., AB79) are capable of binding to cynomolgus monkey (cyno) CD38, providing a useful animal model for preclinical evaluation of dosing, toxicity, efficacy, and the like.
[0112] Another advantage of the anti-CD38 antibodies of the invention is that they can be used to screen for other antibodies that compete for binding to CD-38 at the same epitope and that may be useful in the methods and unit dosages of the invention.
[0113] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings commonly understood by those skilled in the art. The meaning and scope of those terms should be clear. However, in case of any potential ambiguity, the definitions provided herein shall take precedence over any dictionary or attendant definitions. Furthermore, unless the context requires otherwise, singular terms shall include the plural and plural terms shall include the singular. The term "or" includes "and / or" unless otherwise specified. Furthermore, the use of the terms "including", "includes" or "included" is not limiting. Terms such as "element" and "component" include both elements and components that include one unit and elements and components that include more than one subunit, unless otherwise specifically specified.
[0114] In general, the nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and proteins, and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout the specification, unless otherwise indicated. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. The nomenclatures used in connection with, and laboratory procedures and techniques for, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation, delivery, and treatment of patients.
[0115] All heading and section designations are used for clarity and reference purposes only and should not be construed as limiting in any way For example, those skilled in the art will understand the utility of combining various aspects of the disclosure from different headings and sections as appropriate in accordance with the spirit and scope of the invention as described herein.
[0116] In order that the present invention may be more readily understood, selected terms are defined below.
[0117] The terms "human CD38" and "human CD38 antigen" refer to the amino acid sequence of SEQ ID NO: 1, or a functional fragment thereof, such as an epitope, as defined herein (Table 1). Generally, CD38 has a short intracytoplasmic tail, a transmembrane domain, and an extracellular domain. The terms "cynomolgus CD38" and "cynomolgus CD38 antigen" refer to the amino acid sequence of SEQ ID NO: 2, which is 92% identical to the amino acid sequence of human CD38 (Table 1). Synonyms for CD38 include cyclic ADP ribose hydrolase, cyclic ADP ribose-hydrolase 1, ADP ribosyl cyclase, ADP-ribosyl cyclase 1, cADPr hydrolase 1, CD38-rs1, I-19, NIM-R5 antigen, 2'-phospho-cyclic-ADP-ribose transferase, 2'-phospho-ADP-ribosyl cyclase, 2'-phospho-cyclic-ADP-ribose transferase, 2'-phospho-ADP-ribosyl cyclase, and T10. [Table 1]
[0118] The terms "therapeutically effective amount" and "therapeutically effective dosage" refer to an amount of a therapeutic agent that is sufficient to reduce or alleviate the severity and / or duration of a disorder or one or more symptoms thereof; prevent the disorder from progressing; cause the disorder to regress; prevent the recurrence, onset, manifestation, or progression of one or more symptoms associated with the disorder; or enhance or improve the prophylactic or therapeutic effect(s) of another therapeutic agent (e.g., a prophylactic or therapeutic agent) at dosages and for periods of time necessary to achieve the desired therapeutic outcome. A therapeutically effective amount may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the pharmaceutical agent to elicit a desired response in the individual. A therapeutically effective amount of an antibody is one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. A therapeutically effective amount of an antibody for tumor treatment may be measured by its ability to stabilize disease progression. The ability of a compound to inhibit cancer may be evaluated in animal model systems that are predictive of efficacy in human tumors.
[0119] The terms "patient" and "subject" include both humans and other animals, particularly mammals. Thus, the compositions, dosages, and methods disclosed herein are applicable to both human and veterinary therapy. In one embodiment, the patient is a mammal, e.g., a human.
[0120] The term "disease in which binding to CD38 is indicated" refers to a disease in which binding of a binding partner (e.g., an anti-CD38 antibody of the invention) to CD38 provides a prophylactic or curative effect, including alleviation of one or more symptoms of the disease. Such binding may include blocking other factors or binding partners of CD38, neutralization of CD38, ADCC, CDC, complement activation, or other methods to inhibit the activation of CD38. or some other mechanism by which the disease is prevented or treated. Factors and binding partners of CD38 include autoantibodies to CD38, which are blocked by the anti-CD38 antibodies of the invention. Such binding may be adaptive as a result of expression of CD38 by a cell or a subset of cells, e.g., MM cells, whereby providing a binding partner of CD38 to a subject results in removal, e.g., lysis, of the cells, e.g., via hemolysis or apoptosis. Such expression of CD38 may be the result of normal, overexpressed, inappropriately expressed CD38, or activation of CD38, e.g., compared to normal cells or compared to other cell types during either non-disease or disease states.
[0121] The term "blood cancer" refers to malignant neoplasms of blood-forming tissues and includes leukemia, lymphoma, and multiple myeloma. Non-limiting examples of conditions associated with aberrant CD38 expression include multiple myeloma (Jackson et al. (1988) Clin. Exp. Immunol. 72:351-356), B-cell chronic lymphocytic leukemia (B-CLL) (Durig et al. (2002) Leukemia 16:30-35, Morabito et al. (2001) Leukemia Res. 25:927-932, Marinov et al. (1993) Neoplasma 40(6):355-358, and Jelinek et al. (2001) Br. J. Haematol. 115:854-861), acute lymphoblastic leukemia (Keyhani et al. (1999) Leukemia Res. 24:153-159, and Marinov et al. (1993) Neoplasma 40(6):355-358), chronic myelogenous leukemia (Marinov et al. (1993) Neoplasma 40(6):355-358), acute myelogenous leukemia (Keyhani et al. (1999) Leukemia Res. 24:153-159), chronic lymphocytic leukemia (CLL), chronic myelogenous or chronic myelogenous leukemia (CML), acute myelogenous or acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), hairy cell leukemia (HCL), myelodysplastic syndromes (MDS), and all subtypes and stages of these leukemias (e.g., CML blast phase (BP), chronic phase (CP), or accelerated phase (AP)), and other hematological disorders, which are defined by morphological, histochemical, and immunological techniques well known to those skilled in the art.
[0122] The terms "neoplasm" and "neoplastic condition" refer to a condition associated with cell proliferation characterized by a loss of normal control resulting in one or more symptoms including uncontrolled growth, lack of differentiation, dedifferentiation, local tissue invasion, and metastasis.
[0123] The term "isolated antibody" refers to an antibody that is substantially free of other antibodies with different antigen specificity. For example, an isolated antibody that specifically binds to CD38 is substantially free of antibodies that specifically bind to antigens other than CD38. However, an isolated antibody that specifically binds to an epitope, isoform, or variant of human CD38 or cynomolgus CD38 may have cross-reactivity to other related antigens from other species, such as, for example, homologs of CD38 species. Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals.
[0124] The terms "red blood cell", "RBC", and "erythrocyte" refer to hemoglobin-containing blood cells derived from bone marrow that carry oxygen to cells and tissues and carbon dioxide back to the respiratory tract. They are also called erythrocytes, red blood corpuscles, hematides, and erythroid cells.
[0125] The terms "specific binding," "specifically binds to," and "specific for," in reference to the interaction of a particular antibody, protein, or peptide with an antigen, epitope, or other chemical species, refer to binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining the binding of a molecule compared to the binding of a control molecule, which is generally a molecule of similar structure that has no binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target. The anti-CD38 antibodies of the invention specifically bind to the CD38 ligand. The terms "specific binding," "specifically binds to," and "specific for" also refer to the dependence of the interaction on the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species. For example, an antibody recognizes and binds to a specific protein structure, rather than recognizing and binding to the protein as a whole. If an antibody is specific for epitope "A," then in a reaction containing labeled "A" and an antibody, the presence of a molecule containing epitope A (or free, unlabeled A) will reduce the amount of labeled A bound to the antibody. Specific binding to a particular antigen or epitope is, for example, at least about 10 -4 M, at least about 10 -5 M, at least about 10 -6 M, at least about 10 -7 M, at least about 10 -8 M, at least about 10 -9 M, at least about 10 -10 M, at least about 10 -11 M, at least about 10 -12Specific binding to a particular antigen or epitope can be demonstrated by an antibody having a KD of at least M, where KD refers to the dissociation rate of a particular antibody-antigen interaction. Typically, an antibody that specifically binds to an antigen will have a KD of 20 times, 50 times, 100 times, 500 times, 1000 times, 5,000 times, 10,000 times or more greater than that of the antigen or epitope in question relative to a control molecule. Specific binding to a particular antigen or epitope can also be demonstrated by an antibody having a K A or Ka for the antigen or epitope that is at least 20 times, 50 times, 100 times, 500 times, 1000 times, 5,000 times, 10,000 times or more greater than that of the control molecule in question, where K A or Ka refers to the association rate of a particular antibody-antigen interaction.
[0126] The term "over a period of time" refers to any period of time, such as minutes, hours, days, months, or years. For example, over a period of time can refer to at least 10 minutes, at least 15 minutes, at least 30 minutes, at least 60 minutes, at least 75 minutes, at least 90 minutes, at least 105 minutes, at least 120 minutes, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 22 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 1 month, at least 1 year, or any time interval therebetween. In other words, the antibody from the composition may be absorbed by the individual to whom it is administered over a period of at least 10 minutes, at least 15 minutes, at least 30 minutes, at least 60 minutes, at least 75 minutes, at least 90 minutes, at least 105 minutes, at least 120 minutes, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 22 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 1 month, at least 1 year, or any time interval therebetween.
[0127] A composition that "substantially" comprises an ingredient means that the composition contains more than about 80% by weight of the ingredient. Preferably, the composition contains more than about 90% by weight of the ingredient. Preferably, the composition contains more than about 95% by weight of the ingredient. Preferably, the composition contains more than about 90% by weight of the ingredient. The composition may comprise greater than about 97% by weight of the component. Preferably, the composition may comprise greater than about 98% by weight of the component. Preferably, the composition may comprise greater than about 99% by weight of the component.
[0128] The term "about" refers to a close range in number, degree, amount, time, etc., with only minor variations in the order of magnitude, up to 10%.
[0129] The term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle suitable for administering a compound of the invention to a mammal. Carriers include liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials involved in carrying or transporting the compound of interest from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient. In one embodiment, the pharmaceutically acceptable carrier is suitable for intravenous administration. In another embodiment, the pharmaceutically acceptable carrier is suitable for locoregional injection. In another embodiment, the pharmaceutically acceptable carrier is suitable for subcutaneous administration. In another embodiment, the pharmaceutically acceptable carrier is suitable for subcutaneous injection.
[0130] The term "pharmaceutical composition" refers to a preparation suitable for administration to a subject and treatment of a disease. When the anti-CD38 antibodies of the present invention are administered as pharmaceuticals to a mammal, such as a human, they can be administered "as is" or as a pharmaceutical composition containing the anti-CD38 antibody in combination with a pharmaceutical acceptable carrier and / or other excipients. The pharmaceutical composition can be in the form of a unit dosage form for administration of a particular dosage of the anti-CD38 antibody at a particular concentration, amount, or volume. Pharmaceutical compositions are provided that include an anti-CD38 antibody, either alone or in combination with a prophylactic agent, a therapeutic agent, and / or a pharmaceutical acceptable carrier. Suitably, the pharmaceutical composition may include a unit dosage form according to the present invention, either alone or in combination with a prophylactic agent, a therapeutic agent, and / or a pharmaceutical acceptable carrier. Suitably, the pharmaceutical composition may include a human anti-CD38 antibody as described herein, either alone or in combination with a prophylactic agent, a therapeutic agent, and / or a pharmaceutical acceptable carrier.
[0131] A conventional antibody structural unit typically comprises a tetramer. Each tetramer is typically composed of two identical pairs of polypeptide chains, each pair having one "light" chain (typically having a molecular weight of about 25 kDa) and one "heavy" chain (typically having a molecular weight of about 50-70 kDa). Human light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, which define the antibody isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM has subclasses, including, but not limited to, IgM1 and IgM2. Thus, "isotype" refers to any of the subclasses of immunoglobulins, defined by the chemical and antigenic properties of their constant regions. The known human immunoglobulin isotypes are IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM1, IgM2, IgD, and IgE. Therapeutic antibodies can also include hybrids of isotypes and / or subclasses.
[0132] Each variable heavy (VH) and variable light (VL) region (approximately 100-110 amino acids in length) is composed of three hypervariable regions called "complementarity determining regions" (CDRs) and four framework regions (FRs) (approximately 15-30 amino acids in length), which are arranged from amino-terminus to carboxy-terminus in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. "Variable" refers to the fact that the sequences of the CDRs vary significantly among antibodies, thereby determining unique antigen-binding sites.
[0133] The hypervariable region generally consists of amino acid residues from about 24 to 34 (LCDR1, "L" represents light chain), 50 to 56 (LCDR2), and 89 to 97 (LCDR3) in the light chain variable region, and amino acid residues from about 31 to 35B (HCDR1, "H" represents heavy chain), 50 to 65 (HCDR2), and 95 to 102 (HCDR3) in the heavy chain variable region (Kabat et al. (1991) Sequences Of Proteins Of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD), and / or those residues that form the hypervariable loops (e.g., residues 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3) in the light chain variable region, and 26-32 (HCDR1), 53-55 (HCDR2), and 96-101 (HCDR3) in the heavy chain variable region) (Chothia and Lesk (1987) J. Mol. Biol. 196:901-917).
[0134] The Kabat numbering system is commonly used when referring to residues in variable domains (approximately residues 1-107 for light chain variable regions and residues 1-113 for heavy chain variable regions) (e.g., Kabat et al. (1991) Sequences Of Proteins Of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD), while the EU numbering system is used for the Fc region.
[0135] The term "immunoglobulin (Ig) domain" refers to a region of an immunoglobulin having a unique tertiary structure. In addition to the variable domain, each heavy and light chain has constant domains, namely the constant heavy (CH) domain, the constant light (CL) domain, and the hinge domain. In the context of IgG antibodies, each IgG isotype has three CH regions. The carboxy-terminal portion of each HC and LC defines the constant region primarily responsible for effector functions. Thus, the "CH" domains in the context of IgG are as follows: "CH1" refers to positions 118-220 according to the EU index as in Kabat; "CH2" refers to positions 237-340 according to the EU index as in Kabat; and "CH3" refers to positions 341-447 according to the EU index as in Kabat.
[0136] Another type of Ig domain of the heavy chain is the hinge region. The term "hinge region" refers to a flexible polypeptide that includes the amino acids between the first and second constant domains of an antibody. Structurally, the CH1 domain of an IgG ends at EU position 220, and the CH2 domain of an IgG starts at residue EU position 237. Thus, for IgG, the antibody hinge is defined herein to include positions 221 (D221 in IgG1) to 236 (G236 in IgG1), where the numbering is according to the EU index as in Kabat. In some embodiments, for example in the context of the Fc region, the lower hinge is included, which "lower hinge" generally refers to positions 226 or 230.
[0137] The term "Fc region" refers to a polypeptide that includes the constant region of an antibody excluding the first constant region immunoglobulin domain, and in some instances, a portion of the hinge. Thus, Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge at the N-terminus of these domains. In the case of IgA and IgM, Fc may also include the J chain. In the case of IgG, the Fc domain includes immunoglobulin domains Cγ2 and Cγ3 (Cγ2 and Cγ3), and the lower hinge region between Cγ1 (Cγ1) and Cγ2 (Cγ2). Although the boundaries of the Fc region may vary, the heavy chain Fc region of human IgG is usually defined to include residues C226, or P230, to the carboxyl terminus, where numbering is according to the EU index as in Kabat. In some embodiments, amino acid modifications are made to the Fc region to alter binding to one or more FcγR or FcRn receptors, for example, as described more fully below.
[0138] CD38 antibody Thus, the present invention provides isolated anti-CD38 antibodies that specifically bind to human and primate CD38 proteins, utilized in subcutaneous administration methods and unit dosage forms. Particularly useful in the present invention are antibodies that bind to both human and primate CD38 proteins, particularly those found in cynomolgus monkeys (Macaca fascicularis) and primate CD38 proteins. Primates such as Macaca fascicularis, Crab eating macaques, also referred to herein as "cynos," are used in clinical trials.
[0139] In some embodiments, the anti-CD38 antibodies of the invention interact with CD38 at several amino acid residues, including K121, F135, Q139, D141, M142, E239, W241, S274, C275, K276, F284, V288, K289, N290, P291, E292, D293, and S294, based on the numbering of the human sequence. Suitably, the anti-CD38 antibodies of the invention may interact with CD38 at several amino acid residues, including K121, F135, Q139, D141, M142, E239, W241, S274, C275, K276, F284, V288, K289, N290, P291, E292, D293, and S294, based on the numbering of the human sequence, of SEQ ID NO:1. Suitably, the anti-CD38 antibodies of the invention interact with CD38 at several amino acid residues including K121, F135, Q139, D141, M142, E239, W241, F274, C275, K276, F284, V288, K289, N290, P291, E292, D293, and S294 of SEQ ID NO: 2. Note that these residues are identical in both humans and cynomolgus monkeys, except that in cynomolgus monkeys, S274 is actually F274. These residues may represent immunodominant epitopes and / or residues within the footprint of a particular antigen-binding peptide.
[0140] In some embodiments, an anti-CD38 antibody for use according to the invention comprises a heavy chain comprising the following CDR amino acid sequences: GFTFDDYG (SEQ ID NO:3, HCDR1 AB79), ISWNGGKT (SEQ ID NO:4, HCDR2 AB79), and ARGSLFHDSSGFYFGH (SEQ ID NO:5, HCDR3 AB79) or variants of those sequences with up to three amino acid changes. In some embodiments, an antibody for use according to the invention comprises a light chain comprising the following CDR amino acid sequences: SSNIGDNY (SEQ ID NO:6, LCDR1 AB79), RDS (SEQ ID NO:7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO:8, LCDR3 AB79) or variants of those sequences with up to three amino acid changes. In some embodiments, an antibody for use according to the invention comprises a heavy chain comprising the following CDR amino acid sequences: GFTFDDYG (SEQ ID NO:3, HCDR1 AB79), ISWNGGKT (SEQ ID NO:4, HCDR2 AB79), ARGSLFHDSSGFYFGH (SEQ ID NO:5, HCDR3 AB79) or variants of those sequences with up to three amino acid changes, and a light chain comprising the following CDR amino acid sequences: SSNIGDNY (SEQ ID NO:6, LCDR1 AB79), RDS (SEQ ID NO:7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO:8, LCDR3 AB79) or variants of those sequences with up to three amino acid changes. In some embodiments, an anti-CD38 antibody comprises the following CDR amino acid sequences: GFTFDDYG (SEQ ID NO:3, HCDR1 AB79), ISWNGGKT (SEQ ID NO:4, HCDR2 AB79), and ARGSLFHDSSGFYFGH (SEQ ID NO:5, HCDR3 AB79). In some embodiments, the antibody comprises a heavy chain comprising the following CDR amino acid sequences: SSNIGDNY (SEQ ID NO:6, LCDR1 AB79), RDS (SEQ ID NO:7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO:8, LCDR3 AB79). In some embodiments, the antibody comprises a light chain comprising the following CDR amino acid sequences: GFTFDDYG (SEQ ID NO:3, HCDR1 AB79), SSNIGDNY (SEQ ID NO:6, LCDR1 AB79), RDS (SEQ ID NO:7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO:8, LCDR3 AB79). AB79), ISWNGGKT (SEQ ID NO:4, HCDR2 AB79), ARGSLFHDSSGFYFGH (SEQ ID NO:5, HCDR3 AB79), and a light chain comprising the following CDR amino acid sequences: SSNIGDNY (SEQ ID NO:6, LCDR1 AB79), RDS (SEQ ID NO:7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO:8, LCDR3 AB79). In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO:9. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, the remainder of the sequence may have at least 80% sequence identity to SEQ ID NO:9. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, the remainder of the sequence may have at least 85% sequence identity to SEQ ID NO:9. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 90% sequence identity to SEQ ID NO:9. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 95% sequence identity to SEQ ID NO:9. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 97% sequence identity to SEQ ID NO:9. Suitably, the VH chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, the remainder of the sequence having at least 99% sequence identity to SEQ ID NO:9.
[0141] In some embodiments, the antibody comprises a heavy chain comprising the variable heavy (VH) chain amino acid sequence of SEQ ID NO:9. EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSSASTKGPSVFPLA (sequence number 9).
[0142] In some embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 10. Suitably, the VL chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, and the remainder of the VL sequence may have at least 80% sequence identity to SEQ ID NO: 10. Suitably, the VL chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, and the remainder of the VL sequence may have at least 85% sequence identity to SEQ ID NO: 10. Suitably, the VL chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, and the remainder of the VL sequence may have at least 90% sequence identity to SEQ ID NO: 10. Suitably, the VL chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, and the remainder of the VL sequence may have at least 95% sequence identity to SEQ ID NO: 10. Suitably, the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, with the remainder of the VL sequence having at least 97% sequence identity to SEQ ID NO:10. Suitably, the VL chain may comprise the CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, with the remainder of the VL sequence having at least 99% sequence identity to SEQ ID NO:10.
[0143] In some embodiments, the antibody comprises the variable light (VL) chain amino acid sequence of SEQ ID NO:10. Contains the light chain. QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVLGQPKANPTVTLFPPSSEEL (sequence number 10).
[0144] In some embodiments, the antibody comprises a heavy chain comprising the VH chain amino acid sequence of SEQ ID NO: 9, or a variant thereof as described herein, and a light chain comprising the VL chain amino acid sequence of SEQ ID NO: 10, or a variant thereof as described herein.
[0145] As will be appreciated by those of skill in the art, the variable heavy and light chains may be linked to human IgG constant domain sequences, typically IgG1, IgG2, or IgG4.
[0146] In some embodiments, the antibody comprises a heavy chain (HC) comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO:11. Suitably, the heavy chain may comprise CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and the remainder of the heavy chain may have at least 80% sequence identity to SEQ ID NO:11. Suitably, the heavy chain may comprise CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and the remainder of the heavy chain may have at least 85% sequence identity to SEQ ID NO:11. Suitably, the heavy chain may comprise CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and the remainder of the heavy chain may have at least 90% sequence identity to SEQ ID NO:11. Suitably, the heavy chain may comprise CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and the remainder of the heavy chain may have at least 95% sequence identity to SEQ ID NO:11. Suitably, the heavy chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and the remainder of the heavy chain may have at least 97% sequence identity to SEQ ID NO:11. Suitably, the heavy chain may comprise the CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and the remainder of the heavy chain may have at least 99% sequence identity to SEQ ID NO:11.
[0147] In some embodiments, the antibody comprises the heavy chain (HC) amino acid sequence of SEQ ID NO:11. EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (sequence number 11).
[0148] In some embodiments, the antibody comprises a light chain (LC) comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 12. Suitably, the light chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, and the remainder of the light chain may have at least 80% sequence identity to SEQ ID NO: 12. Suitably, the light chain may comprise CDR sequences as defined by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, and the remainder of the light chain may have at least 85 ... Suitably, the light chain may comprise CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, and the remainder of the light chain may have at least 90% sequence identity to SEQ ID NO:12. Suitably, the light chain may comprise CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, and the remainder of the light chain may have at least 95% sequence identity to SEQ ID NO:12. Suitably, the light chain may comprise CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, and the remainder of the light chain may have at least 97% sequence identity to SEQ ID NO:12. Suitably, the light chain may comprise CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, and the remainder of the light chain may have at least 99% sequence identity to SEQ ID NO:12.
[0149] In some embodiments, the antibody comprises the light chain (LC) amino acid sequence of SEQ ID NO:12. QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (sequence number 12). In some embodiments, the antibody comprises the HC amino acid sequence of SEQ ID NO: 11, or a variant thereof as described herein, and the LC amino acid sequence of SEQ ID NO: 12, or a variant thereof as described herein.
[0150] The present invention encompasses antibodies that bind to both human and cynomolgus CD38 and interact with at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the following amino acid residues: K121, F135, Q139, D141, M142, E239, W241, S274, C275, K276, F284, V288, K289, N290, P291, E292, D293, and S294 of SEQ ID NO:1 and SEQ ID NO:2, based on human numbering. Preferably, the antibody can interact with at least 90% of these amino acid residues. Preferably, the antibody can interact with at least 95% of these amino acid residues. Preferably, the antibody can interact with at least 97% of these amino acid residues. Preferably, the antibody can interact with at least 98% of these amino acid residues. Preferably, the antibody can interact with at least 99% of these amino acid residues. Preferably, the antibody can interact with at least 14 (e.g., at least 15 or at least 16) of the following amino acids, based on human numbering: K121, F135, Q139, D141, M142, E239, W241, S274, C275, K276, F284, V288, K289, N290, P291, E292, D293, and S294 of SEQ ID NO:1 and SEQ ID NO:2.
[0151] In some embodiments, the antibody is full-length. By "full-length antibody" herein is meant the structure that constitutes the natural biological form of an antibody, including variable and constant regions, including one or more modifications as outlined herein.
[0152] Alternatively, the antibody may be of various structures, including, but not limited to, antibody fragments, monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as "antibody mimetics"), chimeric antibodies, humanized antibodies, antibody fusions (sometimes referred to as "antibody conjugates"), and fragments of each of them. Specific antibody fragments include (i) a Fab fragment consisting of the VL, VH, CL, and CH1 domains, (ii) an Fd fragment consisting of the VH and CH1 domains, (iii) an Fv fragment consisting of the VL and VH domains of a single antibody, (iv) a dAb fragment (Ward et al. (1989) Nature 341:544-546) consisting of a single variable portion, (v) an isolated CDR region, and (vi) two linked Fab fragments. (vii) single chain Fv molecules (scFv), in which the VH and VL domains are linked by a peptide linker, allowing the two domains to associate and form an antigen-binding site (Bird et al. (1988) Science 242:423-426, Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883); (viii) bispecific single chain Fvs (WO 03 / 11161); and (ix) "diabodies" or "triabodies", which are multivalent or multispecific fragments constructed by gene fusion (Tomlinson et al. (2000) Methods Enzymol. 326:461-479, WO 94 / 13804, Holliger et al. al.(1993)Proc.Natl.Acad.Sci.USA 90:6444-6448).
[0153] Preferably, the antibody may be a Fab fragment. Preferably, the antibody may be an Fv fragment. Preferably, the antibody may be an Fd fragment. Preferably, the antibody structure may be an isolated CDR region. Preferably, the antibody may be an F(ab')2 fragment. Preferably, the antibody may be an scFv fragment.
[0154] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion 1 day, 2 days, 4 days, 8 days, 10 days, 15 days, 20 days, 25 days, and / or 30 days after administration.
[0155] The term "significant level of cell depletion" may refer to a level of cell depletion that has adverse consequences for a subject.
[0156] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion one day after administration.
[0157] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion after two days of administration.
[0158] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion after 4 days of administration.
[0159] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion after 8 days of administration.
[0160] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion 10 days after administration.
[0161] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion 15 days after administration.
[0162] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion after 20 days of administration.
[0163] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion after 25 days of administration.
[0164] In some embodiments, the antibody does not cause significant levels of red blood cell and / or platelet depletion 30 days after administration.
[0165] Suitably, the antibodies for use according to the invention may result in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% depletion of RBCs following treatment. Suitably, the antibodies for use according to the invention may result in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% depletion of platelets following treatment.
[0166] antibody modification The present invention further provides variant anti-CD38 antibodies. Thus, there are several modifications that can be made to the antibodies of the present invention, including, but not limited to, amino acid modifications in the CDRs (affinity maturation), amino acid modifications in the Fc region, glycosylation variants, other types of covalent modifications, etc.
[0167] The term "variant" refers to a polypeptide that differs from that of a parent polypeptide. Amino acid variants can include amino acid substitutions, insertions, and deletions. In general, variants can include any number of modifications, so long as the function of the protein is still present, as described herein. That is, for example, in the case of an amino acid variant made with the CDRs of AB79, the antibody should still specifically bind to both human and cynomolgus CD38. The term "variant Fc region" refers to an Fc sequence that differs from that of the wild-type or parent Fc sequence due to at least one amino acid modification. The Fc variant may refer to the Fc polypeptide itself, a composition that includes the Fc variant polypeptide, or an amino acid sequence. For example, when an amino acid variant is made with an Fc region, the variant antibody should maintain the functionality required for the particular use or indication of the antibody. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions can be utilized, such as 1-10, 1-5, 1-4, 1-3, and 1-2 substitutions. Suitable modifications can be made at one or more positions as generally outlined in, for example, U.S. Patent Application Nos. 11 / 841,654, 12 / 341,769, U.S. Patent Publication Nos. 2004013210, 20050054832, 20060024298, 20060121032, 20060235208, 20070148170, and U.S. Patent Nos. 6,737,056, 7,670,600, and 6,086,875 (all of which are expressly incorporated by reference in their entireties), particularly for specific amino acid substitutions that increase binding to Fc receptors.
[0168] Suitably, the variants maintain the functionality of the parent sequence, i.e., the variants are functional variants. Suitably, the antibodies comprising the variant sequence maintain the functionality of the parent antibody, i.e., the antibodies comprising the variant sequence are capable of binding to human CD38. Suitably, treatment with the variants may result in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% depletion of RBCs. Suitably, treatment with the variants may result in less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% depletion of platelets.
[0169] The variants can be considered in terms of similarity (ie, amino acid residues having similar chemical properties / functions), or preferably, the variants are expressed in terms of sequence identity.
[0170] Sequence comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These publicly and commercially available computer programs can calculate the percent sequence identity between two or more sequences.
[0171] For example, it may be desirable to have one to five modifications in the Fc region and one to five modifications in the Fv region of a wild-type or engineered protein. The variant polypeptide sequence will preferably have at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the parent sequence (e.g., the variable region, constant region, and / or heavy and light chain sequences of AB79). Suitably, the variant may have at least 80% sequence identity to the parent sequence. Suitably, the variant may have at least 85% sequence identity to the parent sequence. Suitably, the variant may have at least 90% sequence identity to the parent sequence. Suitably, the variant may have at least 92% sequence identity to the parent sequence. Suitably, the variant may have at least 95% sequence identity to the parent sequence. Suitably, a variant may have at least 97% sequence identity to the parent sequence. Suitably, a variant may have at least 98% sequence identity to the parent sequence. Suitably, a variant may have at least 99% sequence identity to the parent sequence.
[0172] In one embodiment, sequence identity is determined over the entire sequence. In one embodiment, sequence identity is determined over the entire candidate sequence being compared to a sequence listed herein.
[0173] The term "amino acid substitution" refers to the replacement of an amino acid at a specific position in a parent polypeptide sequence with another amino acid. For example, the substitution S100A refers to a variant polypeptide in which the serine at position 100 is replaced with alanine. Preferably, the amino acid substitution can be a conservative amino acid substitution. Preferably, the variant can include one or more, for example, two or three, conservative amino acid substitutions. Amino acids with similar biochemical properties can be defined as amino acids that can be replaced through conservative substitution.
[0174] Unless otherwise expressly provided herein by reference to specific individual amino acids, amino acids may be substituted with conservative substitutions as listed below. An aliphatic polar uncharged amino acid may be a cysteine, serine, threonine, methionine, asparagine, or glutamine residue. An aliphatic polar charged amino acid may be an aspartic acid, glutamic acid, lysine, or arginine residue. An aromatic amino acid may be a histidine, phenylalanine, tryptophan, or tyrosine residue. Conservative substitutions may be made, for example, according to Table 2 below. Amino acids in the same block in the second column, and preferably in the same line in the third column, may be substituted for each other.
[0175] [Table 2]
[0176] The term "amino acid insertion" refers to an amino acid insertion at a particular position in a parent polypeptide sequence. This means the addition of.
[0177] The term "amino acid deletion" refers to the removal of an amino acid at a particular position in a parent polypeptide sequence.
[0178] The terms "parent antibody" and "precursor antibody" refer to an unmodified antibody that is subsequently modified to generate a variant. In an embodiment, the parent antibody herein is AB79. In an embodiment, the parent antibody herein comprises a VH chain having the amino acid sequence of SEQ ID NO: 9 and a VL chain having the amino acid sequence of SEQ ID NO: 10. In an embodiment, the parent antibody herein comprises a heavy chain amino acid sequence of SEQ ID NO: 11 and a light chain amino acid sequence of SEQ ID NO: 12. The parent antibody may refer to the polypeptide itself, a composition comprising the parent antibody, or the amino acid sequence encoding it. Thus, the term "parent Fc polypeptide" refers to an Fc polypeptide that is modified to generate a variant.
[0179] The terms "wild type," "wild-type (WT)," and "native" refer to an amino acid sequence or nucleotide sequence found in nature, including allelic variations. A wild-type protein, polypeptide, antibody, immunoglobulin, IgG, etc., has an amino acid sequence or nucleotide sequence that has not been intentionally modified.
[0180] In some embodiments, one or more amino acid modifications are made in one or more of the CDRs of anti-CD38 antibody.Generally, only 1, 2 or 3 amino acids are replaced in any single CDR, and generally, 4, 5, 6, 7, 8, 9 or 10 or less changes are made in a set of CDRs.However, it should be understood that any combination of none, 1, 2 or 3 replacements in any CDR can be independently and optionally combined with any other replacements.
[0181] In some instances, amino acid modifications in the CDRs are referred to as "affinity maturation." An "affinity matured" antibody is an antibody that has one or more modification(s) in one or more CDRs that results in an improved affinity of the antibody for the antigen, compared to a parent antibody that does not have the modification(s) that results in an improved affinity of the antibody for the antigen. In some instances, it may be desirable to decrease the affinity of the antibody for its antigen.
[0182] Affinity maturation can be carried out to increase the binding affinity of an antibody for an antigen by at least about 10%-50%, 100%, 150%, or more, or 1-5 fold, compared to the "parent" antibody. Preferred affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies can be produced by known procedures (e.g., Marks et al. (1992) Biotechnol. 10:779-783, Barbas et al. (1994) Proc. Nat. Acad. Sci. USA 91:3809-3813, Shier et al. (1995) Gene 169:147-155, Yelton et al. (1995) J. Immunol. 155:1994-2004, Jackson et al. (1995) J. Immunol. 154(7):3310-9, and Hawkins et al. (1995) J. Immunol. 154(7):3310-9). et al. (1992) J. Mol. Biol. 226:889-896).
[0183] Alternatively, amino acid modifications that are "silent", e.g., do not significantly alter the affinity of the antibody for antigen, can be made, e.g., in one or more of the CDRs of an antibody of the invention. These can be made for a number of reasons, including optimization of expression (as can be made to a nucleic acid encoding an antibody of the invention).
[0184] Thus, variant CDRs and antibodies are included within the definition of the CDRs and antibodies of the invention. That is, the antibodies of the invention can comprise amino acid modifications in one or more of the CDRs set forth in SEQ ID NOs: 3 to 8. Additionally, as outlined below, amino acid modifications can also be made independently and optionally in any region outside of the CDRs, including the framework and constant regions.
[0185] In some embodiments, a variant antibody of AB79 is described that is specific for human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2). This antibody is composed of six CDRs, each of which may differ from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and / or SEQ ID NO:8 by 0, 1, or 2 amino acid substitutions.
[0186] In addition to the modifications outlined above, other modifications can be made. For example, the molecule can be stabilized by incorporating disulfide bridges linking the VH and VL domains (Reiter et al. (1996) Nature Biotech. 14:1239-1245). Additionally, there are various covalent modifications of antibodies that can be made, as outlined below.
[0187] Covalent modifications of antibodies are included within the scope of the present invention and are generally, but not always, performed post-translationally. For example, some types of covalent modifications of antibodies are introduced into the molecule by reacting specific amino acid residues of the antibody with organic derivatizing agents capable of reacting with selected side chains or with the N- or C-terminal residues.
[0188] In some embodiments, the anti-CD38 antibodies of the invention specifically bind to one or more residues or regions in CD38 while at the same time not cross-reacting with other proteins that share homology to CD38, such as BST-1 (bone marrow stromal cell antigen 1) and / or Mo5 (also known as CD157).
[0189] Typically, lack of cross-reactivity means less than about 5% competitive inhibition between the molecules when assessed by ELISA and / or FACS analysis under suitable assay conditions and with sufficient amounts of the molecules.
[0190] Inhibition of CD38 activity and reduction of side effects The disclosed antibodies may be utilized in blocking ligand-receptor interactions or inhibiting receptor component interactions. The anti-CD38 antibodies of the present invention may be "blocking" or "neutralizing". The term "neutralizing antibody" refers to an antibody whose binding to CD38 results in the inhibition of CD38 biological activity, such as its ability to interact with ligands, enzymatic activity, signal transduction, and in particular its ability to cause activated lymphocytes. The inhibition of CD38 biological activity can be assessed by one or more of several standard in vitro or in vivo assays known in the art.
[0191] The terms "inhibit binding" and "block binding" (e.g., when referring to inhibiting / blocking binding of a CD38 antibody to CD38) encompass both partial and complete inhibition / blocking. Inhibiting / blocking binding of a CD38 antibody to CD38 may reduce or alter the normal level or type of cell signaling that occurs when a CD38 antibody binds to CD38 without inhibition or blocking. Inhibiting and blocking are also intended to include any measurable decrease in the binding affinity of a CD38 antibody to CD38 when contacted with an anti-CD38 antibody compared to a ligand not contacted with an anti-CD38 antibody, for example, at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100% blocking of binding of a CD38 antibody to CD38. Preferably, blocking of binding of a CD38 antibody to CD38 may be at least about 70%. Preferably, blocking of binding of a CD38 antibody to CD38 may be at least about 10%. Blockade of binding to 8 can be at least about 80%. Suitably, blocking of binding of CD38 antibodies to CD38 can be at least about 90%.
[0192] The disclosed anti-CD38 antibodies can also inhibit cell growth. The term "inhibit growth" refers to any measurable decrease in cell growth when contacted with an anti-CD38 antibody compared to the growth of the same cells not contacted with an anti-CD38 antibody, for example, at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100% inhibition of cell culture growth. Preferably, the inhibition of growth can be at least about 70%. Preferably, the inhibition of growth can be at least about 80%. Preferably, the inhibition of growth can be at least about 90%.
[0193] In some embodiments, the disclosed anti-CD38 antibodies are capable of depleting activated lymphocytes and plasma cells. The term "depletion" in this context refers to a measurable reduction in serum levels of activated lymphocytes and / or plasma cells in a subject compared to an untreated subject. Generally, there is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100% depletion. Preferably, the depletion can be at least 50%. Preferably, the depletion can be at least 60%. Preferably, the depletion can be at least 70%. Preferably, the depletion can be at least 80%. Preferably, the depletion can be at least 90%. Preferably, the depletion can be 100%. As shown in the Examples below, one particular advantage that the antibodies of the invention exhibit is the recovery of these cells after dosing. Thus, as is known for some treatments (e.g., with anti-CD20 antibodies, for example), cell depletion can persist for long periods of time and cause unwanted side effects. As shown herein, the effects on activated lymphocytes and / or plasma cells are reversible.
[0194] The anti-CD38 antibodies of the present invention allow for reduced side effects compared to prior art anti-CD38 antibodies. In some embodiments, the antibodies for use according to the present invention, such as AB79, do not induce TEAEs. In some embodiments, the antibodies for use according to the present invention, such as AB79, allow for a reduced incidence of TEAEs in a patient population compared to other anti-CD38 antibodies, such as MOR202. TEAEs are typically referred to by grades 1, 2, 3, 4, and 5, with grade 1 being the least severe TEAE and grade 5 being the most severe TEAE. Based on FDA and other guidelines on Common Terminology Criteria for Adverse Events of Oncology Drugs (CTCAE) standards (see, for example, https: / / evs.nci.nih.gov / ftp1 / CTCAE / CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf, and https: / / ctep.cancer.gov / protocoldevelopment / electronic_applications / ctc.htm, and Nilsson and Koke (2001) Drug Inform. J. 35:1289-1299), such grades are generally determined as follows: Grade 1 is mild: no symptoms or mild symptoms; clinical or diagnostic findings only; no treatment required. Grade 2 is moderate: minimal, local, or non-invasive treatment required; age-appropriate instrumental activities of daily living ("ADLs") limitation. Grade 3 is severe or medically significant but not immediately life-threatening: requiring hospitalization or prolonged hospitalization; disabling / inability to function; limitation in self-care ADLs. Grade 4 is life-threatening consequence; requiring emergency intervention. Grade 5 is death related to the AE.
[0195] In some embodiments, an antibody for use according to the invention, e.g., AB79, allows for a reduction in the grade of TEAEs in a patient population compared to other anti-CD38 antibodies, such as MOR202. In some embodiments, an antibody for use according to the invention, e.g., AB79, allows for a reduction in the grade of TEAEs from grade 5 to grade 4 compared to other anti-CD38 antibodies. In some embodiments, an antibody for use according to the invention, e.g., AB79, allows for a reduction in the grade of TEAEs from grade 4 to grade 3 compared to other anti-CD38 antibodies. In some embodiments, an antibody for use according to the invention, e.g., AB79, allows for a reduction in the grade of TEAEs from grade 3 to grade 2 compared to other anti-CD38 antibodies. In some embodiments, an antibody for use according to the invention, e.g., AB79, allows for a reduction in the grade of TEAEs from grade 2 to grade 1 compared to other anti-CD38 antibodies.
[0196] In some embodiments, an antibody for use according to the invention, such as AB79, allows for a reduction in the grade of one or more TEAEs selected from the group consisting of anemia (including hemolytic anemia), thrombocytopenia, fatigue, infusion-related reactions (IRR), leukopenia, lymphopenia, and nausea. In some embodiments, an antibody for use according to the invention, such as AB79, allows for a reduction in the occurrence of one or more TEAEs selected from the group consisting of anemia (including hemolytic anemia), thrombocytopenia, fatigue, infusion-related reactions (IRR), leukopenia, lymphopenia, and nausea.
[0197] In some embodiments, the anti-CD38 antibody results in less than 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, or 1% depletion of RBCs. In some embodiments, the AB79 antibody results in less than 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, or 1% depletion of RBCs. In some embodiments, the AB79 antibody results in less than 10% depletion of RBCs.
[0198] In some embodiments, the anti-CD38 antibody causes less than 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, or 1% depletion of platelets. In some embodiments, the AB79 antibody causes less than 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, or 1% depletion of platelets. In some embodiments, the AB79 antibody causes less than 10% depletion of platelets.
[0199] In some embodiments, diagnostic tests are used to determine the presence and / or grade of anemia, including hemolytic anemia. Diagnostic tests for anemia, including hemolytic anemia, include measuring hemoglobin levels. Generally, hemoglobin levels are interpreted as follows: (i) very mild / absent anemia: ≧12.0 g / dL, (ii) mild: 10-12 g / dL, (iii) moderate: 8-10 g / dL, (iv) severe: 6-8 g / dL, and (v) very severe: ≦6 g / dL. Other diagnostic tests for anemia, including hemolytic anemia, include measuring haptoglobin levels. Generally, a haptoglobin level ≦25 mg / dL is indicative of the presence of anemia, including hemolytic anemia. Other diagnostic tests include the direct antiglobulin test (DAT) (also called the direct Coombs test), which is used to determine whether RBCs are coated in vivo with immunoglobulins, complement, or both.
[0200] In some embodiments, diagnostic tests are used to determine the presence and / or grade of thrombocytopenia. Typically, diagnostic tests for thrombocytopenia include measuring the number of platelets per microliter (μL) of blood. Typically, there are 150×10 platelets per μL of blood. 3 -450×10 3 There are generally <150 x 10 platelets per µL of blood. 3 Thrombocytopenia is diagnosed when there are 70–150 × 10 platelets per μL of blood. 3 Mild thrombocytopenia is generally diagnosed when 20–70 × 10 per μL are present. 3Moderate thrombocytopenia is generally diagnosed when there are <20 × 10 cells per μL of blood. 3 When present, severe thrombocytopenia is commonly diagnosed.
[0201] Signs of disease The antibodies, methods, and dosage units of the present invention find use in a variety of applications, including treating or ameliorating CD38-associated diseases.
[0202] CD38 is expressed in immature hematopoietic cells, downregulated in mature cells, and re-expressed at high levels in activated lymphocytes and plasma cells. For example, high expression of CD38 is found in activated B cells, plasma cells, activated CD4+ T cells, activated CD8+ T cells, NK cells, NKT cells, mature dendritic cells (DCs), and activated monocytes. Certain pathological conditions are associated with cells expressing CD38, and certain pathological conditions are associated with overexpression, high density expression, or upregulated expression of CD38 on the surface of cells. Whether a cell population expresses CD38 can be determined by methods known in the art, such as flow cytometric determination of the percentage of cells in a given population that are labeled with an antibody that specifically binds to CD38, or by immunohistochemical assay, as generally described below for diagnostic applications. For example, a population of cells in which CD38 expression is detected in about 10-30% of the cells may be considered to be weakly positive for CD38, and a population of cells in which CD38 expression is detected in more than about 30% of the cells may be considered to be definitively positive for CD38 (as in Jackson et al. (1988) Clin. Exp. Immunol. 72:351-356), although other criteria can be used to determine whether a population of cells expresses CD38. The density of expression on the surface of the cells can be determined using methods known in the art, such as, for example, flow cytometric measurement of the mean fluorescence intensity of cells fluorescently labeled with an antibody that specifically binds to CD38.
[0203] Therapeutic anti-CD38 antibodies of the invention bind to CD38 positive cells and result in the depletion of these cells through multiple mechanisms of action, including both CDC and ADCC pathways.
[0204] It is known in the art that certain pathologies are associated with cells expressing CD38, and that certain pathologies are associated with overexpression, high density, or upregulated expression of CD38 on the surface of cells. Whether a cell population expresses CD38 can be determined by methods known in the art, such as flow cytometric determination of the percentage of cells in a given population that are labeled with an antibody that specifically binds to CD38, or by immunohistochemical assays, as generally described below with respect to diagnostic applications. For example, a population of cells in which CD38 expression is detected in about 10-30% of the cells can be considered to have a weak positivity for CD38, and a population of cells in which CD38 expression is detected in more than about 30% of the cells can be considered to be definitively positive for CD38 (as in Jackson et al. (1988) Clin. Exp. Immunol. 72:351-356), although other criteria can be used to determine whether a population of cells expresses CD38. The density of expression on the surface of a cell can be determined using methods known in the art, such as, for example, flow cytometric measurement of the mean fluorescence intensity of cells fluorescently labeled with an antibody that specifically binds CD38.
[0205] In one aspect, the present invention provides a method for treating a condition associated with the proliferation of cells expressing CD38, comprising administering to a patient a pharmacologic effective amount of the disclosed antibody. In some embodiments, the condition is cancer, and in certain embodiments, the cancer is a hematological cancer. In some embodiments, the condition is multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, B-cell lymphoma, or Burkitt's lymphoma. In some embodiments, the condition is multiple myeloma.
[0206] In some embodiments of the invention, the hematological cancer is selected from the group of chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, and acute lymphocytic leukemia. In some embodiments of the invention, the blood cancer is chronic lymphocytic leukemia. In some embodiments of the invention, the blood cancer is chronic myelogenous leukemia. In some embodiments of the invention, the blood cancer is acute myelogenous leukemia. In some embodiments of the invention, the blood cancer is acute lymphocytic leukemia.
[0207] In some embodiments, the condition is multiple myeloma.
[0208] CLL is the most common adult leukemia in the Western world. It is characterized by a progressive clonal proliferation of mature-appearing lymphocytes affecting lymph nodes and other lymphoid tissues, infiltrating bone marrow and present in peripheral blood. The B-cell subtype (B-CLL) accounts for the majority of cases.
[0209] B-cell chronic lymphocytic leukemia (B-CLL) B-CLL is an incurable disease characterized by the progressive expansion of anergic monoclonal B-lineage cells that accumulate in the bone marrow and peripheral blood in a long-lasting manner over many years. CD38 expression is considered an independent poor prognostic factor for B-CLL (Hamblin et al. (2002) Blood 99:1023-9).
[0210] B-CLL is characterized by two subtypes: indolent and aggressive. These clinical phenotypes are correlated with the presence or absence of somatic mutations in the immunoglobulin heavy chain variable region (IgVH) gene. As used herein, indolent B-CLL refers to disorders in subjects with mutated IgVH genes and / or one or more clinical phenotypes associated with indolent B-CLL. As used herein, the phrase aggressive B-CLL refers to disorders in subjects with unmutated IgVH genes and / or one or more clinical phenotypes associated with aggressive B-CLL.
[0211] The current standard treatment for B-CLL is palliative, primarily with the cytostatic drugs chlorambucil or fludarabine. If relapse occurs, combination therapy is often initiated using fludarabine and cyclophosphamide in combination with rituximab (a monoclonal antibody against CD20) or alemtuzumab (a monoclonal antibody against CD52). In one study, 35 patients with relapsed or refractory aggressive B-cell NHL received high-dose chemotherapy (HCT) followed by rituximab 375 mg / m starting on day 40. 2 was administered weekly for four doses, and repeated four more doses starting on day 180. Rituximab infusions were well tolerated, with only one grade 3 / 4 infusion-related toxicity. An unexpected adverse event observed in this study was delayed neutropenia in more than half of the patients (19 / 35 patients, 46 episodes of grade 3 or 4 neutropenia, Kosmas et al. (2002) Leukemia 16:2004-2015 (can be found online at https: / / www.nature.com / articles / 2402639)). In another study, six patients received alemtuzumab by intravenous infusion three times a week, every other day, for 12 weeks. The dose was titrated daily (3, 10, then 30 mg) until tolerated by the patient. The main TEAEs were anemia, neutropenia (6 / 6 patients each), and thrombocytopenia (5 / 6 patients) in hematological adverse events (Ishizawa et al. (2017) Jpn. J. Clin. Oncol. 47(1):54-60). Thus, there is a significant unmet medical need for treatment of B-CLL with reduced hematological adverse events. In some embodiments, a method of treating B-CLL with the disclosed anti-CD38 antibodies is provided, which may be performed with combination therapy, optionally and independently including any of the above drugs, as outlined below.
[0212] Multiple myeloma (MM) Multiple myeloma (MM) is a B-cell lineage disease characterized by the neoplastic proliferation of plasma cells in the bone marrow. Myeloma is a malignant disorder of the MM. Pharmacological findings in healthy volunteers supported further investigation of MM (Fedyk et al. (2018) Blood 132:3249, incorporated herein by reference in its entirety). The proliferation of myeloma cells causes a variety of effects, including lytic lesions (holes) in bone, reduced red blood cell count, abnormal protein production (with collateral damage to kidneys, nerves, and other organs), reduced immune system function, and elevated blood calcium levels (hypercalcemia). Currently, treatment options include chemotherapy, preferably accompanied by autologous stem cell transplantation (ASCT) when possible. These treatment regimens show moderate response rates. However, only minor changes in overall survival have been observed, with median survival times being approximately 3 years. Thus, there is a significant unmet medical need for the treatment of multiple myeloma. In some embodiments, methods of treating multiple myeloma using the disclosed antibodies are provided.
[0213] Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic pre-malignant disorders characterized by monoclonal plasma cell proliferation in the bone marrow and the absence of end-organ damage.
[0214] Smoldering multiple myeloma (SMM) is an asymptomatic proliferative disorder of plasma cells with a high risk of progression to symptomatic or active multiple myeloma (Kyle et al. (2007) N. Engl. J. Med. 356(25):2582-2590). International consensus criteria to define SMM were adopted in 2003 and require patients to have M protein levels >30 g / L and / or clonal plasma cells >10% in bone marrow (Internat. Myeloma Working Group (2003) Br. J. Haematol. 121:749-757). Patients must not have organ involvement or associated tissue damage such as bone lesions or symptoms. Recent studies have identified two subsets of SMM: i) patients with progressive disease and ii) patients with non-progressive disease (Internat. Myeloma Working Group (2003) Br. J. Haematol. 121:749-757).
[0215] SMM resembles monoclonal gammopathy of undetermined significance (MGUS) because of the absence of end-organ damage (Kyle et al. (2007) N. Engl. J. Med. 356(25):2582-2590). Clinically, however, SMM is much more likely to progress to active multiple myeloma or amyloidosis at 20 years (78% chance in SMM vs. 21% chance in MGUS) (Kyle et al. (2007) N. Engl. J. Med. 356(25):2582-2590).
[0216] International consensus criteria for defining MGUS require that patients have M protein levels <30 g / L, <10% plasma cells in the bone marrow, and an absence of associated tissue damage, including organ or bone lesions or symptoms (Internat. Myeloma Working Group (2003) Br. J. Haematol. 121:749-757).
[0217] Systemic light-chain amyloidosis Amyloidosis refers to a family of protein misfolding diseases in which different types of proteins aggregate as extracellular insoluble fibrils. They are complex, multisystem diseases. A common type of systemic amyloidosis is systemic light chain (AL) amyloidosis (Gertz et al. (2004) Am. Soc. Hematol. 2004:257-82). Like multiple myeloma, AL amyloidosis is a plasma cell neoplasm. AL amyloidosis is caused by the production of excess monoclonal immunoglobulin free light chains. Amyloidosis is a rare, progressive, fatal disease of the elderly caused by a small clonal population of plasma cells in the bone marrow that cause amyloidosis. Once in circulation, these pathological light chains misfold, aggregate, and deposit as fibrillar material in the internal organs. The amyloid fibril deposits are the same free light chain proteins secreted by the clonal plasma cells (Cohen and Comenzo (2010) Am. J. Hematol. 2010:287-94; Merlini and Bellotti (2003) New England J. Med. 349(6):583-96; Murray et al. (2010) Blood (ASH Annual Meeting Abstracts) 116(21):abstr 1909). End-organ damage and ultimately death occur as a result of this amyloid fibril deposition. Therapies that suppress clonal plasma cells may alleviate AL amyloidosis disease by eliminating the factories that produce circulating toxic free light chains, which in turn may improve organ function and survival. There are no regulatory approved treatments for systemic AL amyloidosis. The drugs used are those used to treat multiple myeloma. Thus, there is a significant unmet medical need for the treatment of patients with AL amyloidosis, and targeting CD38 on plasma cells is a meaningful therapeutic strategy.
[0218] Other CD38-related pathologies The antibodies, methods, and dosage units of the invention find use in a variety of applications, including the treatment or alleviation of CD38-associated diseases, such as diseases and conditions associated with inflammation, and immune diseases, particularly diseases associated with activated lymphocytes. The anti-CD38 antibodies of the invention bind to CD38 positive cells and result in the depletion of these cells, such as activated lymphocytes, through multiple mechanisms of action, including both CDC and ADCC pathways.
[0219] Thus, any autoimmune disease that exhibits either increased expression of CD38 or an increased number of CD38 expressing cells as a component of the disease may be treated with the antibodies of the invention, including but not limited to allogeneic islet graft rejection, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, antineutrophil cytoplasmic autoantibodies (ANCA), autoimmune disease of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune myocarditis, autoimmune neutropenia, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, autoimmune urticaria, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman syndrome, celiac sprue dermatitis, chronic fatigue immune deficiency syndrome, chronic inflammatory demyelinating polyneuropathy, Churg's syndrome, and the like. Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, factor VIII deficiency, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barré, Goodpasture's syndrome, graft-versus-host disease (GVHD), Hashimoto's thyroiditis, hemophilia A, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy, IgM polyneuropathy, immune-mediated thrombocytopenia, juvenile arthritis, Kawasaki disease, lichen planus plantus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, type 1 diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychrondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia agammaglobinulinemia), primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, solid organ graft rejection, stiff-man syndrome, systemic lupus erythematosus, systemic light-chain amyloidosis, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thrombotic thrombocytopenic purpura, ulcerative colitis, uveitis, vasculitis such as dermatitis herpetiformis vasculitis, vitiligo, and Wegner's granulomatosis.
[0220] Particularly useful in some embodiments are systemic lupus erythematosus (SLE), The antibody is for use in the diagnosis and / or treatment of several diseases, including but not limited to autoimmune diseases, including but not limited to rheumatoid arthritis (RA), inflammatory bowel disease (IBD), ulcerative colitis, systemic light chain amyloidosis, and graft-versus-host disease. In one embodiment, the disease is systemic lupus erythematosus (SLE). In one embodiment, the disease is rheumatoid arthritis (RA). In one embodiment, the disease is inflammatory bowel disease (IBD). In one embodiment, the disease is ulcerative colitis. In one embodiment, the disease is graft-versus-host disease. In one embodiment, the disease is systemic light chain amyloidosis.
[0221] Thus, patients with high plasma cell content, such as, for example, SLE patients who exhibit high plasma cell levels, as well as RA patients who have been shown to be unresponsive to CD20-based therapies, may be treated.
[0222] Antibody Compositions for In Vivo Administration Formulations of antibodies used according to the invention are prepared for storage in the form of a lyophilized formulation or aqueous solution by mixing the antibody having the desired purity with optional pharma- ceutically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences 16th edition (1980) Osol, A. Ed.).
[0223] The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably active compounds with complementary activities that do not adversely affect each other. For example, it may be desirable to provide antibodies with other specificities. Alternatively, or in addition, the composition may contain cytotoxic agents, cytokines, growth inhibitors, and / or small molecule antagonists. Such molecules are preferably present in combination in amounts that are effective for the intended purpose.
[0224] Subcutaneous The anti-CD38 antibodies described herein, such as AB79, can be administered in sufficient dosage to be therapeutically effective, thereby allowing subcutaneous administration.Subcutaneous administration is considered to be the least invasive administration mode and the most versatile, and therefore the desirable administration mode that can be used for short-term and long-term therapy.In some embodiments, subcutaneous administration can be performed by injection.In some embodiments, when multiple injections or multiple devices are required, the site of injection or device can be rotated.
[0225] Thus, subcutaneous formulations are much easier for patients to self-administer, especially since the formulation may need to be taken periodically throughout the patient's life (e.g., beginning as early as the first year of a child's life). Furthermore, the ease and speed of subcutaneous delivery allows for increased patient compliance and more rapid availability of medication when needed. Thus, the subcutaneous formulations of anti-CD38 antibodies provided herein offer substantial advantages over the prior art and solve certain unmet needs.
[0226] In some embodiments, the antibody of the present invention is administered to a subject via subcutaneous route according to known methods. In some embodiments, the antibody of the present invention can be administered by subcutaneous injection. In a specific embodiment, the subcutaneous formulation is subcutaneously injected into the same site of the patient for repeated or continuous injections (e.g., administered into the upper arm, the front of the thigh, the lower abdomen, or the upper back). In other embodiments, the subcutaneous formulation is subcutaneously injected into different or alternating sites of the patient. Single or multiple administration of the formulation can be employed.
[0227] In some embodiments, the subcutaneous unit dosage forms described herein can be used in the treatment of cancer. In some embodiments, the subcutaneous unit dosage forms described herein can be used in the treatment of hematological cancers. In some embodiments, the subcutaneous unit dosage forms described herein can be used to treat multiple myeloma.
[0228] In some embodiments, the antibodies of the present invention have increased bioavailability compared to prior art antibodies. In some embodiments, the bioavailability of the antibodies of the present invention is increased by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% or more compared to prior art antibodies that bind to human RBCs. In some embodiments, the bioavailability of the antibodies of the present invention is increased by 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, or 300% or more compared to prior art antibodies that bind to human RBCs. Preferably, the bioavailability may be increased by 50%. Preferably, the bioavailability may be increased by 60%. Preferably, the bioavailability may be increased by 70%. Preferably, the bioavailability may be increased by 80%. Preferably, the bioavailability may be increased by 90%.
[0229] In some embodiments, the increased bioavailability allows for subcutaneous administration.
[0230] In some embodiments, the antibodies of the invention lead to depletion of NK cells, B cells, and / or T cells. In some embodiments, the antibodies of the invention allow increased depletion of NK cells compared to depletion of B cells or T cells. In some embodiments, the antibodies of the invention allow increased depletion of NK cells compared to B cells, and increased depletion of NK cells compared to T cells. In some embodiments, the antibodies of the invention allow increased depletion of NK cells compared to B cells, and increased depletion of B cells compared to T cells. In some embodiments, the antibodies of the invention allow increased depletion of NK cells compared to B cells, and increased depletion of B cells compared to T cells. Suitably, the antibodies of the invention bind to CD38 - CD38 compared to cells + This may allow for increased cell depletion.
[0231] In certain embodiments, the bioavailability of the anti-CD38 antibodies described herein after subcutaneous administration is at least 50% to at least 80% compared to intravenous administration normalized to the same dose. In certain embodiments, the bioavailability of the anti-CD38 antibodies described herein after subcutaneous administration is at least 60% to at least 80% compared to intravenous administration normalized to the same dose. In certain embodiments, the bioavailability of the anti-CD38 antibodies described herein after subcutaneous administration is at least 50% to 70% compared to intravenous administration normalized to the same dose. In certain embodiments, the bioavailability of the anti-CD38 antibodies described herein after subcutaneous administration is at least 55% to 65% compared to intravenous administration normalized to the same dose. In certain embodiments, the bioavailability of the anti-CD38 antibodies described herein after subcutaneous administration is at least 55% to 70% compared to intravenous administration normalized to the same dose.
[0232] In certain embodiments, the bioavailability of an anti-CD38 antibody described herein following subcutaneous administration is at least 40%, at least 45%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, or at least 85% relative to intravenous administration normalized to the same dose. Suitably, the bioavailability is at least 40%, at least 45%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, or at least 85% relative to intravenous administration normalized to the same dose. The bioavailability may be at least 50% as compared to intravenous administration normalized to the same dose. Preferably, the bioavailability may be at least 60% as compared to intravenous administration normalized to the same dose. Preferably, the bioavailability may be at least 70% as compared to intravenous administration normalized to the same dose. Preferably, the bioavailability may be at least 80% as compared to intravenous administration normalized to the same dose. Preferably, the bioavailability may be at least 90% as compared to intravenous administration normalized to the same dose.
[0233] In some embodiments, the disclosure provides methods in which the bioavailability of an antibody of the invention following subcutaneous administration is 50%-80% compared to intravenous administration normalized to the same dose.
[0234] In some embodiments, the disclosure provides methods in which the bioavailability of an antibody of the invention following subcutaneous administration is at least 50% compared to intravenous administration normalized to the same dose.
[0235] In some embodiments, the disclosure provides methods, wherein the bioavailability of an antibody of the invention following subcutaneous administration is at least 55% compared to intravenous administration normalized to the same dose.
[0236] In some embodiments, the disclosure provides methods in which the bioavailability of an antibody of the invention following subcutaneous administration is at least 60% compared to intravenous administration normalized to the same dose.
[0237] In some embodiments, the disclosure provides methods, wherein the bioavailability of an antibody of the invention following subcutaneous administration is at least 65% compared to intravenous administration normalized to the same dose.
[0238] In some embodiments, the disclosure provides methods in which the bioavailability of an antibody of the invention following subcutaneous administration is at least 70% compared to intravenous administration normalized to the same dose.
[0239] In some embodiments, the disclosure provides methods in which the bioavailability of an antibody of the invention following subcutaneous administration is at least 75% compared to intravenous administration normalized to the same dose.
[0240] In some embodiments, the disclosure provides methods in which the bioavailability of an antibody of the invention following subcutaneous administration is at least 80% compared to intravenous administration normalized to the same dose.
[0241] In some embodiments, the disclosure provides a unit dosage form comprising an anti-CD38 antibody as described herein, wherein the anti-CD38 antibody results in less than 10% depletion of RBCs.
[0242] In some embodiments, the disclosure provides a unit dosage form comprising an anti-CD38 antibody as described herein, wherein the anti-CD38 antibody results in less than 10% depletion of platelets.
[0243] In certain embodiments, the anti-CD38 antibodies described herein are administered subcutaneously in a single bolus injection. In certain embodiments, the anti-CD38 antibodies described herein are administered subcutaneously monthly. In certain embodiments, the anti-CD38 antibodies described herein are administered subcutaneously every two weeks. In certain embodiments, the anti-CD38 antibodies described herein are administered subcutaneously every week. In certain embodiments, the anti-CD38 antibodies described herein are administered subcutaneously in a single bolus injection. The anti-CD38 antibody is administered subcutaneously twice a week. In certain embodiments, the anti-CD38 antibody described herein is administered subcutaneously every day. In certain embodiments, the anti-CD38 antibody described herein is administered subcutaneously every 12 hours. In certain embodiments, the anti-CD38 antibody described herein is administered subcutaneously every 8 hours. In certain embodiments, the anti-CD38 antibody described herein is administered subcutaneously every 6 hours. In certain embodiments, the anti-CD38 antibody described herein is administered subcutaneously every 4 hours. In certain embodiments, the anti-CD38 antibody described herein is administered subcutaneously every 2 hours. In certain embodiments, the anti-CD38 antibody described herein is administered subcutaneously every hour.
[0244] In some embodiments, the subcutaneous unit dosage form is administered in a dosage of about 45 mg to about 1,800 mg. In some embodiments, the subcutaneous unit dosage form comprises a sufficient amount to administer a dosage of about 135 mg to about 1,800 mg. In some embodiments, the subcutaneous unit dosage form comprises a sufficient amount to administer a dosage of about 600 mg to about 1,800 mg. In some embodiments, the subcutaneous unit dosage form comprises a sufficient amount to administer a dosage of about 1,200 mg to about 1,800 mg. In some embodiments, the subcutaneous unit dosage form comprises a sufficient amount to administer a dosage of about 45 mg to about 1,200 mg. In some embodiments, the subcutaneous unit dosage form comprises a sufficient amount to administer a dosage of about 135 mg to about 1,200 mg. In some embodiments, the subcutaneous unit dosage form comprises a sufficient amount to administer a dosage of about 600 mg to about 1,200 mg. In some embodiments, the subcutaneous unit dosage form contains an amount sufficient to administer a dosage of about 45 mg to about 135 mg. In some embodiments, the subcutaneous unit dosage form contains an amount sufficient to administer a dosage of about 45 mg to about 600 mg. In some embodiments, the subcutaneous unit dosage form contains an amount sufficient to administer a dosage of about 135 mg to about 600 mg. In some embodiments, the dosage is in mg per kilogram of body weight. In some embodiments, the dosage is a daily dosage.
[0245] Unit dosage form In some embodiments, the therapeutic anti-CD38 antibody is formulated as part of a unit dosage form. In some embodiments, the anti-CD38 antibody comprises a heavy chain comprising the following CDR amino acid sequences: GFTFDDYG (SEQ ID NO: 3, HCDR1 AB79), ISWNGGKT (SEQ ID NO: 4, HCDR2 AB79), and ARGSLFHDSSGFYFGH (SEQ ID NO: 5, HCDR3 AB79) or variants of those sequences with up to three amino acid changes. In some embodiments, the antibody comprises a light chain comprising the following CDR amino acid sequences: SSNIGDNY (SEQ ID NO: 6, LCDR1 AB79), RDS (SEQ ID NO: 7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO: 8, LCDR3 AB79) or variants of those sequences with up to three amino acid changes. In some embodiments, the antibody comprises a heavy chain comprising the following CDR amino acid sequences: GFTFDDYG (SEQ ID NO:3, HCDR1 AB79), ISWNGGKT (SEQ ID NO:4, HCDR2 AB79), ARGSLFHDSSGFYFGH (SEQ ID NO:5, HCDR3 AB79) or variants of those sequences with up to three amino acid changes, and a light chain comprising the following CDR amino acid sequences: SSNIGDNY (SEQ ID NO:6, LCDR1 AB79), RDS (SEQ ID NO:7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO:8, LCDR3 AB79) or variants of those sequences with up to three amino acid changes. In some embodiments, the antibody comprises a heavy chain comprising the following CDR amino acid sequences: GFTFDDYG (SEQ ID NO:3, HCDR1 AB79), ISWNGGKT (SEQ ID NO:4, HCDR2 AB79), and ARGSLFHDSSGFYFGH (SEQ ID NO:5, HCDR3 AB79). In some embodiments, the antibody comprises a light chain comprising the following CDR amino acid sequences: SSNIGDNY (SEQ ID NO:6, LCDR1 AB79), RDS (SEQ ID NO:7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO:8, LCDR ... and a light chain comprising the following CDR amino acid sequences: SSNIGDNY (SEQ ID NO:6, LCDR1 AB79), RDS (SEQ ID NO:7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO:8, LCDR3 AB79). In some embodiments, the antibody comprises a heavy chain comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO:9. Suitably, the heavy chain may comprise the following CDR amino acid sequences: GFTFDDYG (SEQ ID NO:3, HCDR1 AB79), ISWNGGKT (SEQ ID NO:4, HCDR2 AB79), and ARGSLFHDSSGFYFGH (SEQ ID NO:5, HCDR3 AB79), and the remainder of the heavy chain may have at least 80% sequence identity to SEQ ID NO:9. In some embodiments, the antibody comprises a heavy chain comprising the variable heavy (VH) chain amino acid sequence of SEQ ID NO:9. EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSSASTKGPSVFPLA (sequence number 9).
[0246] In some embodiments, the antibody comprises a light chain comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 10. Suitably, the light chain may comprise the following CDR sequences: SSNIGDNY (SEQ ID NO: 6, LCDR1 AB79), RDS (SEQ ID NO: 7, LCDR2 AB79), and QSYDSSLSGS (SEQ ID NO: 8, LCDR3 AB79), and the remainder of the light chain may have at least 80% sequence identity to SEQ ID NO: 10. In some embodiments, the antibody comprises a light chain comprising the variable light (VL) chain amino acid sequence of SEQ ID NO: 10. QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVLGQPKANPTVTLFPPSSEEL (sequence number 10).
[0247] In some embodiments, the antibody comprises a heavy chain comprising the VH chain amino acid sequence of SEQ ID NO: 9, or a variant thereof as described herein, and a light chain comprising the VL chain amino acid sequence of SEQ ID NO: 10, or a variant thereof as described herein.
[0248] As will be appreciated by those skilled in the art, the variable heavy and light chains may be bound to human IgG constant domain sequences, typically IgG1, IgG2, or IgG4. In some embodiments, the antibody comprises a heavy chain (HC) having an amino acid sequence having at least 80% sequence identity to SEQ ID NO:11. Suitably, the heavy chain may comprise CDR sequences as defined by SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and the remainder of the heavy chain may have at least 80% sequence identity to SEQ ID NO:11. In some embodiments, the antibody comprises a heavy chain (HC) amino acid sequence of SEQ ID NO:11. EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (sequence number 11).
[0249] In some embodiments, the antibody comprises a light chain (LC) having an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 12. Suitably, the light chain may comprise CDR sequences as defined by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, and the remainder of the light chain may have at least 80% sequence identity to SEQ ID NO: 12. In some embodiments, the antibody comprises a light chain (LC) amino acid sequence of SEQ ID NO:12. QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (sequence number 12).
[0250] In some embodiments, the antibody comprises the HC amino acid sequence of SEQ ID NO: 11, or a variant thereof as described herein, and the LC amino acid sequence of SEQ ID NO: 12, or a variant thereof as described herein.
[0251] In some embodiments, the formulation comprising an anti-CD38 antibody is in a unit dosage form. In some embodiments, the unit dosage form comprises a sufficient amount to administer a dosage of about 45 mg to about 1,800 mg. In some embodiments, the unit dosage form comprises a sufficient amount to administer a dosage of about 135 mg to about 1,800 mg. In some embodiments, the unit dosage form comprises a sufficient amount to administer a dosage of about 600 mg to about 1,800 mg. In some embodiments, the unit dosage form comprises a sufficient amount to administer a dosage of about 1,200 mg to about 1,800 mg. In some embodiments, the unit dosage form comprises a sufficient amount to administer a dosage of about 45 mg to about 1,200 mg. In some embodiments, the unit dosage form comprises a sufficient amount to administer a dosage of about 135 mg to about 1,200 mg. In some embodiments, the unit dosage form comprises a sufficient amount to administer a dosage of about 600 mg to about 1,200 mg. In some embodiments, the unit dosage form contains an amount sufficient to administer a dosage of about 45 mg to about 135 mg. In some embodiments, the unit dosage form contains an amount sufficient to administer a dosage of about 45 mg to about 600 mg. In some embodiments, the unit dosage form contains an amount sufficient to administer a dosage of about 135 mg to about 600 mg. In some embodiments, the dosage is in mg per kilogram of body weight. In some embodiments, the dosage is a daily dosage.
[0252] In some embodiments, the unit dosage form of the anti-CD38 antibody provided herein may further comprise one or more pharma- ceutically acceptable excipients, carriers, and / or diluents. In some embodiments, the anti-CD38 antibody is provided as a pharmaceutical composition comprising a unit dosage form according to the invention. Suitably, the pharmaceutical composition may further comprise one or more pharma- ceutically acceptable excipients, carriers, and / or diluents.
[0253] Dosage regimen is adjusted to provide the optimum desired response (e.g., therapeutic response). For example, a single bolus may be administered, or several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. The composition may be formulated in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein may refer in some embodiments to physically discrete units suitable as unitary dosages for treating subjects, each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
[0254] The specifications for the unit dosage forms of the present invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such active compounds for the treatment of individuals.
[0255] The effective dosage and dosage regimen of the anti-CD38 antibodies used in the present invention depends on the type and severity of the disease or condition to be treated and can be determined by one skilled in the art.
[0256] In one embodiment, the anti-CD38 antibody is administered subcutaneously at a weekly dosage of about 45 to about 1,800 mg. Preferably, the weekly dosage may be about 135 to about 1,800 mg. Preferably, the weekly dosage may be about 600 to about 1,800 mg. Preferably, the weekly dosage may be about 1,200 to about 1,800 mg. Preferably, the weekly dosage may be about 45 to about 1,200 mg. Preferably, the weekly dosage may be about 135 to about 1,200 mg. Preferably, the weekly dosage may be about 600 to about 1,200 mg. Preferably, the weekly dosage may be about 45 to about 135 mg. Preferably, the weekly dosage may be about 45 to about 600 mg. Preferably, the weekly dosage may be about 135 to about 600 mg.
[0257] Such administration may be repeated 1 to 14 times, for example 3 to 5 times. An exemplary non-limiting range for the therapeutically effective amount of the anti-CD38 antibody used in the present invention is about 45 to about 1,800 mg. Preferably, the dosage may be about 135 to about 1,800 mg. Preferably, the dosage may be about 600 to about 1,800 mg. Preferably, the dosage may be about 1,200 to about 1,800 mg. Preferably, the dosage may be about 45 to about 1,200 mg. Preferably, the dosage may be about 135 to about 1,200 mg. Preferably, the dosage may be about 600 to about 1,200 mg. Preferably, the dosage may be about 45 to about 135 mg. Preferably, the dosage may be about 45 to about 600 mg. Suitably, the dosage may be from about 135 to about 600 mg.
[0258] As non-limiting examples, treatment according to the present invention can be administered using single or divided doses 24, 18, 12, 8, 6, 4, 2, or hourly, or any combination thereof, for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 11 From about 45 to about 1,800 mg per day, e.g., 45, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1010, 1020, 1030, 1040, 1050, 1060, 1070, 1080, 1090, 1100, 1110, 1120, 1130, 1140, 1150, , 280, 300, 320, 340, 360, 380, 400, 420, 440, 460, 480, 500, 520, 540, 560, 580, 600, 620, 640, 660, 680, 700, 720, 740, 760, 780, 800, 820, 840, 860, 880, 900, 920, 940, 960, 980, 1000, 1020, 1040, 1060, 1080, 1100, 1120, 1140, 116 The antibody may be provided as a daily dosage of 0, 1180, 1200, 1220, 1240, 1260, 1280, 1300, 1320, 1340, 1360, 1380, 1400, 1420, 1440, 1460, 1480, 1500, 1520, 1540, 1560, 1580, 1600, 1620, 1640, 1660, 1680, 1700, 1720, 1740, 1760, 1780, or 1800 mg. Preferably, the daily dosage is about 45 mg. Preferably, the daily dosage is about 100 mg. Preferably, the daily dosage is about 135 mg. Preferably, the daily dosage is about 150 mg. Preferably, the daily dosage may be about 200 mg. Preferably, the daily dosage may be about 300 mg. Preferably, the daily dosage may be about 400 mg. Preferably, the daily dosage may be about 500 mg. Preferably, the daily dosage may be about 600 mg. Preferably, the daily dosage may be about 700 mg. Preferably, the daily dosage may be about 800 mg. Preferably, the daily dosage may be about 900 mg. Preferably, the daily dosage may be about 1000 mg. Preferably, the daily dosage may be about 1100 mg. Preferably, the daily dosage may be about 1200 mg. Preferably, the daily dosage may be about 1300 mg. Preferably, the daily dosage may be about 1400 mg. Preferably, the daily dosage may be about 1500 mg. Preferably, the daily dosage may be about 1600 mg. Preferably, the daily dosage may be about 1700 mg. Suitably, the daily dosage may be about 1800 mg.
[0259] In one embodiment, the anti-CD38 antibody is administered in a weekly dosage of about 45 to about 1,800 mg. Preferably, the weekly dosage may be about 135 to about 1,800 mg. Preferably, the weekly dosage may be about 600 to about 1,800 mg. Preferably, the weekly dosage may be about 1,200 to about 1,800 mg. Preferably, the weekly dosage may be about 45 to about 1,200 mg. Preferably, the weekly dosage may be about 135 to about 1,200 mg. Preferably, the weekly dosage may be about 600 to about 1,200 mg. Preferably, the weekly dosage may be about 45 to about 135 mg. Preferably, the weekly dosage may be about 45 to about 600 mg. Preferably, the weekly dosage may be about 135 to about 600 mg. Such administration may be repeated, for example, 1 to 14 times, such as 3 to 5 times. Administration may be by continuous infusion over a period of 1 to 24 hours, such as a period of 1 to 12 hours. Such regimens may be repeated one or more times as necessary, for example, after 6 or 12 months. Dosage may be determined or adjusted by measuring the amount of a compound of the invention in the blood immediately after administration, for example, by taking a biological sample and using an anti-idiotypic antibody that targets the antigen-binding region of an anti-CD38 antibody.
[0260] In one embodiment, the therapeutic antibody is formulated at a concentration of 100 mg / ml. In some embodiments, a 1.75 mL, 2.0 mL, 2.25 mL, or 2.5 mL volume is injected into the thigh, abdomen, or arm. In some embodiments, a 1.75 mL, 2.0 mL, 2.25 mL, or 2.5 mL volume is injected into the thigh or abdomen. In some embodiments, a 2.25 mL volume is injected into the thigh or abdomen. In some embodiments, the doses are administered over a 4 hour, 6 hour, 8 hour, or 10 hour period. In some embodiments, the doses are administered over an 8 hour period. In some embodiments, 2, 4, 6, or 8 doses are administered. In some embodiments, the doses are administered every 2 hours.
[0261] In a further embodiment, the anti-CD38 antibody is administered once a week for 2 to 12 weeks. Suitably, the antibody may be administered once a week for, for example, 3 to 10 weeks. Suitably, the antibody may be administered once a week for, for example, 4 to 8 weeks. Suitably, the antibody may be administered once a week for, for example, 5 to 7 weeks.
[0262] In one embodiment, the anti-CD38 antibody is administered subcutaneously at a frequency that varies over time. Suitably, the antibody may be administered once a week for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until unacceptable toxicity is observed or the subject discontinues treatment for other reasons.
[0263] In one embodiment, the anti-CD38 antibody is administered by maintenance therapy, for example, once weekly for a period of six months or more.
[0264] In one embodiment, the anti-CD38 antibody is administered in a regimen that includes one infusion of the anti-CD38 antibody, followed by an infusion of an anti-CD38 antibody conjugated to a radioisotope, which may be repeated, for example, 7-9 days later.
[0265] In one embodiment, the disclosure provides a unit dosage form comprising an anti-CD38 antibody as described herein, wherein the anti-CD38 antibody results in less than 10% depletion of RBCs.
[0266] In one embodiment, the disclosure provides a unit dosage form comprising an anti-CD38 antibody as described herein, wherein the anti-CD38 antibody results in less than 10% depletion of platelets.
[0267] In some embodiments, the anti-CD38 antibodies for use according to the invention are used in combination with one or more additional therapeutic agents, e.g., chemotherapeutic agents. Non-limiting examples of DNA damaging chemotherapeutic agents include topoisomerase I inhibitors (e.g., irinotecan, topotecan, camptothecin and their analogs or metabolites, and doxorubicin), topoisomerase II inhibitors (e.g., etoposide, teniposide, and daunorubicin), alkylating agents (e.g., melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, decarbazine, cyclosporine ... bazine), methotrexate, mitomycin C, and cyclophosphamide), DNA intercalators (e.g., cisplatin, oxaliplatin, and carboplatin), DNA intercalators and free radical generators such as bleomycin, and nucleoside mimetics (e.g., 5-fluorouracil, capecitibine, gemcitabine, fludarabine, cytarabine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea).
[0268] Chemotherapeutic agents that interfere with cell replication include paclitaxel, docetaxel, and related analogs; vincristine, vinblastine, and related analogs; thalidomide, lenalidomide, and related analogs (e.g., CC-5013 and CC-4047); protein tyrosine kinase inhibitors (e.g., imatinib mesylate and gefitinib); proteasome inhibitors (e.g., bortezomib); NF-κB inhibitors, including inhibitors of IκB kinase; antibodies that bind to proteins overexpressed, inappropriately expressed, or activated in cancer, thereby downregulating cell replication (e.g., trastuzumab, rituximab, cetuximab, and bevacizumab); and other inhibitors of proteins or enzymes known to be upregulated, overexpressed, inappropriately expressed, or activated in cancer, whose inhibition downregulates cell replication.
[0269] In some embodiments, antibodies of the invention may be used prior to, concomitantly with, or following treatment with Velcade® (bortezomib).
[0270] treatment means In the method of the present invention, therapy is used to provide a positive therapeutic response for a disease or condition. The term "positive therapeutic response" refers to the improvement of a disease or condition and / or the improvement of symptoms associated with the disease or condition. For example, a positive therapeutic response may refer to one or more of the following disease improvements: (1) a reduction in the number of neoplastic cells; (2) an increase in the death of neoplastic cells; (3) an inhibition of neoplastic cell survival; (5) an inhibition (i.e., some slowing, preferably halting) of tumor growth; (6) an increase in patient survival rate; and (7) some relief of one or more symptoms associated with the disease or condition.
[0271] The positive therapeutic response in any given disease or condition can be determined by the standardized response criteria specific to that disease or condition.Tumor response can be assessed with respect to changes in tumor morphology (i.e., overall tumor burden, tumor size, etc.) using screening techniques such as magnetic resonance imaging (MRI) scan, X-ray imaging, computed tomography (CT) scan, bone scan imaging, endoscopy, and tumor biopsy sampling, including bone marrow aspiration (BMA) and counting circulating tumor cells.
[0272] In addition to these positive therapeutic responses, subjects undergoing therapy may experience the beneficial effect of improving symptoms associated with the disease. In the case of B-cell neoplasms, subjects may experience a reduction in so-called B symptoms, such as night sweats, fever, weight loss, and / or hives. In the case of pre-malignant conditions, therapy with anti-CD38 therapeutic antibodies may block and / or prolong the time before the onset of associated malignant conditions, such as the onset of multiple myeloma, in subjects with monoclonal gammopathy of undetermined significance (MGUS).
[0273] Improvement in disease may be characterized as a complete response, which term refers to the absence of clinically detectable disease accompanied by normalization of any previously abnormal x-rays, bone marrow, and cerebrospinal fluid (CSF), or in the case of myeloma, abnormal monoclonal proteins.
[0274] Such a response may persist for at least 4-8 weeks, or at least 6-8 weeks, following treatment with the methods of the present invention. Alternatively, the improvement in disease may be classified as being a partial response. The term "partial response" may refer to at least about a 50% reduction in all measurable tumor burden (i.e., the number of malignant cells present in the subject, or the measured size of tumor volume or amount of abnormal monoclonal protein) in the absence of new lesions, which may persist for at least 4-8 weeks, or at least 6-8 weeks.
[0275] Treatment according to the present invention includes a "therapeutically effective amount" of the pharmaceutical agent used.
[0276] The terms "therapeutically effective amount" and "therapeutically effective dosage" refer to an amount of a therapeutic agent that is sufficient to reduce or alleviate the severity and / or duration of a disorder or one or more symptoms thereof; prevent the disorder from progressing; cause regression of the disorder; prevent the recurrence, onset, manifestation, or progression of one or more symptoms associated with the disorder; or enhance or improve the prophylactic or therapeutic effect(s) of another therapeutic agent (e.g., a prophylactic or therapeutic agent) at dosages and for such time periods necessary to achieve the desired therapeutic outcome. A therapeutically effective amount may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the pharmaceutical agent to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. A "therapeutically effective amount" of an antibody for tumor therapy may be measured by its ability to stabilize disease progression. The ability of a compound to inhibit cancer may be evaluated in animal model systems that are predictive of efficacy in human tumors.
[0277] Alternatively, this property of the composition may be evaluated by testing the ability of the compound to inhibit cell growth or induce apoptosis by in vitro assays known to those of skill in the art. A therapeutically effective amount of a therapeutic compound may reduce tumor size or otherwise alleviate symptoms in a subject. One of skill in the art would be able to determine such an amount based on factors such as the size of the subject, the severity of the subject's symptoms, and the particular composition or route of administration selected.
[0278] Anti-CD38 antibody kit In another aspect of the present invention, a kit for treating a disease or condition associated with hematological cancer is provided. In one embodiment, the kit comprises a dose of an anti-CD38 antibody as described herein, such as AB79. In some embodiments, the kit provided herein may contain one or more doses of a liquid or lyophilized formulation as provided herein. When the kit comprises a lyophilized formulation of an anti-CD38 antibody as described herein, such as AB79, the kit will generally also contain a liquid suitable for reconstitution of the liquid formulation, such as sterile water or a pharma- ceutically acceptable buffer. In some embodiments, the kit is administered subcutaneously by a medical professional. The anti-CD38 antibody formulations described herein may be included in a syringe prefilled for clinical or home use.
[0279] In certain embodiments, the kit will be for a single administration or dosing of an anti-CD38 antibody described herein, such as AB79. In other embodiments, the kit may contain multiple doses of an anti-CD38 antibody described herein, such as AB79, for subcutaneous administration. In one embodiment, the kit may include an anti-CD38 antibody formulation described herein pre-filled in a syringe for subcutaneous administration by a medical professional or for home use.
[0280] product In another embodiment, an article of manufacture is provided that contains materials useful for treating the above-mentioned disorders. The article of manufacture includes a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The container may be formed from a variety of materials, such as glass or plastic. The container holds a composition that is effective for treating the condition and may have a sterile access port (e.g., the container may be an intravenous fluid bag, or a vial with a stopper pierceable by a hypodermic needle). The active agent in the composition is an antibody. A label on or associated with the container indicates that the composition is used for treating the condition of choice. The article of manufacture may further include a second container containing a pharma- ceutically acceptable buffer, such as phosphate buffered saline, Ringer's solution, or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts containing instructions for use. EXAMPLES
[0281] Example 1: Model-based characterization of anti-CD38 antibodies in cynomolgus monkeys The anti-CD38 antibody AB79 is distinct from daratumumab (Darzalex™), a cytolytic CD38 monoclonal antibody recently approved for the treatment of multiple myeloma, in that it binds to cynomolgus monkey (cyno) CD38. This unique feature supported the use of cynomolgus monkeys in preclinical studies to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of AB79. To this end, assays were developed to measure drug concentrations, immunogenicity, and to quantify T, B, and NK lymphocytes in the blood of cynomolgus monkeys. These parameters were assessed in eight pharmacological and toxicological preclinical studies. Of the cell populations tested, CD38 is most highly expressed on NK cells. It is therefore assumed that the drug effect on NK cells will most closely resemble the effect on plasmablasts, plasma cells, and other activated lymphocytes, the target cells considered.
[0282] Data were pooled from eight studies in healthy monkeys using a dose range of 0.03-100 mg / kg, and mathematical models were developed to describe the pharmacokinetics and exposure-effect relationships for each of the cell types. Depletion of NK cells was identified as the most sensitive pharmacodynamic effect of AB79. This depletion was described using a turnover model (EC50=34.8 μg / mL for depletion rate), with complete depletion achieved at 0.3 mg / kg IV dosing. Also, a moderate effect on T cell numbers was observed using a direct response model (EC50=9.43 μg / mL), and a moderate effect on B cell numbers using a four-pass compartment model (EC50=19.3 μg / mL for depletion rate). These analyses substantiated the observation that each of the measured lymphocyte subsets was cleared by AB79 at different rates and required different periods of time to deplete the blood compartment.
[0283] Mathematical models describing PK and PD data are useful tools to gain mechanistic and quantitative insight into the relationship between drug exposure and effect (Friberg et al. (2002) J. Clin. Oncol. 20:4713-4721, Mager et al. (Han and Zhou (2011) Ther. Deliv. 2:359-368). The typical PK characteristics of IgG antibodies, including distribution and elimination, and the physiological and genetic similarities between monkeys and humans, can be exploited to explain the pharmacology of AB79 (Glassman et al. (2003) Drug Metab. Dispos. 31:510-518; Han and Zhou (2011) Ther. Deliv. 2:359-368). and Balthasar (2014) Cancer Biol. Med. 11:20-33, Kamath (2016) Drug Discov. Today Technol. 21-22:75-83). Additionally, these models have been successfully applied to predict PK concentrations and PD effects in healthy human subjects (Han and Zhou (2011) Ther. Deliv. 2:359-368).
[0284] Materials and Methods A summary of the monkey studies is presented in chronological order in Table 3. Single-dose studies 2, 7, and 8 were conducted primarily to evaluate the PK and PD of AB79 administered intravenously (IV) and subcutaneously (SC). Repeat-dose studies were conducted to evaluate safety, PK, and PD, including two 4-week studies (Studies 1 and 3) and three 13-week studies (Studies 4, 5, and 6) under GLP conditions. A dosing error occurred in the 13-week study 5. An animal in the lowest dose group received 0.01 mg / kg instead of the intended 0.1 mg / kg at one time point (second dose) and then continued at 0.1 mg / kg. These data were added to the data set along with the correct information of the actual dose administered. Study 6 repeated the low-dose, weekly 0.1 mg / kg group of study 5. All animal studies were conducted in compliance with the Guide for the Care and Use of Laboratory Animals adopted and promulgated by the U.S. National Institutes of Health. [Table 3]
[0285] bioanalysis PK was analyzed using a validated method developed and implemented by Charles River Laboratories (Reno, NV). Briefly, concentrations of AB79 were measured in monkey serum using an indirect enzyme-linked immunosorbent assay (ELISA). A 96-well microtiter format was coated with an anti-idiotypic antibody against AB79. Blanks, standards, and quality control (QC) samples containing various concentrations of AB79 were added to the plate and incubated for 55-65 min at room temperature (RT). After washing the microtiter plate, peroxidase-labeled AffiniPure mouse anti-human IgG (Peroxidase AffiniPure Mouse Anti-Human IgG, Fcγ Fragment Specific, Jackson ImmunoResearch) was added and incubated on the plate for an additional 55-65 min. The plate was washed again, and tetramethylbenzidine (TMB) was added to the wells to develop the chromophore, and color development was stopped by the addition of stop solution (2N sulfuric acid). Absorbance at 450 nm was measured using a SPECTRAmax® 190 microplate reader (Molecular Devices) and AB79 concentrations were calculated using a four-parameter logistic weighting (1 / y 2 ) was calculated using a standard calibration curve. In study 1 (Table 3), the lower limit of quantification (LLOQ) of AB79 in serum was 0.061 μg / mL, and in all other studies it was 0.05 μg / mL.
[0286] Determination of anti-AB79 antibodies (immunogenicity) Screening of monkey sera for anti-drug antibodies (ADA) was analyzed using a qualitative electrochemiluminescence (ECL) method validated and performed by Charles River Laboratories (Reno, NV). Briefly, undiluted serum samples were incubated with 300 mM acetic acid. The acid-dissociated samples were incubated in a mixture of biotinylated AB79, SULFO-TAG-labeled AB79 (labeled at Meso Scale Diagnostics, Charles River Laboratories), and 1.5 M Trizma base to neutralize the acid and form immune complexes. The complexes were then added to a streptavidin-coated MSD plate (Meso Scale Diagnostics) and allowed to bind. After washing, MSD Read Buffer T (Meso Scale Diagnostics) was added to the plate, after which luminescence (light) was generated by exciting SULFO-TAG™ via the electrochemical reaction of Ru(bpy)3 and was read on an MSD Sector 6000 (Meso Scale Diagnostics). The complexes were detected by reading them using a ELISA kit (Diagnostics) and the amount of light emitted correlated with the level of monkey anti-AB79 antibodies present in the serum of each sample.
[0287] Blood cell characterization To assess and compare the levels of AB79 binding between humans and monkeys, blood samples from each were collected in sodium heparin tubes. An aliquot of blood (100 μL) was mixed with the appropriate volume of antibody (Figure 1) and incubated at room temperature for 15-20 minutes in the dark. After incubation, 1 mL of BD FACS lysing solution (1x, BD Biosciences, San Jose, CA) was added to lyse red blood cells, and the cells were incubated at room temperature for 10 minutes in the dark, then centrifuged, decanted, and resuspended in 1 mL of staining buffer containing bovine serum albumin (BD Biosciences). The cells were centrifuged again, decanted, and resuspended in 250 μL of Flow Fix (1% paraformaldehyde in calcium- and magnesium-free Dulbecco's PBS (Life Technologies, Carlsbad, CA)), and fluorescence was measured by flow cytometric analysis using a FACSCanto™ II flow cytometer (BD Biosciences). Monkey NK cells (CD3-, CD159a+), B cells (CD3-, CD20+), Human NK cells (CD3-, CD16 / CD56+), B cells (CD3-, CD19+), and T cells (CD3+) were measured. The mean fluorescence intensity of AB79 staining for each cell population was converted to units of molecules of soluble fluorescence (MOEF) that represent the same amount of fluorescence intensity using a standard curve generated with Rainbow Beads (Spherotech, Lake Forest, IL).
[0288] In the study outlined in Table 3, cells were stained and analyzed using a validated method developed and implemented by Charles River Laboratories (Reno, NV). Monkey blood samples were collected in sodium heparin tubes before and at multiple time points after AB79 treatment, and specific lymphocyte populations were measured by flow cytometric analysis using a FACSCanto™ II flow cytometer (BD Biosciences). Commercially available antibodies and CD38 antibodies (Ab19, U.S. Patent No. 8,362,211) were titrated to optimal concentrations for staining. Monkey CD38+ / -, T cell (CD3+), B cell (CD3- / CD20+), and natural killer (NK) cell (CD3- / CD20- / CD16+) populations were identified, and lymphocytes were quantified using CD45TruCount™ tubes (BD Biosciences). Approximately 100 μL aliquots of each blood sample were placed into appropriate wells of a 96-well plate, and antibodies were added at the indicated volumes, mixed, and incubated at room temperature in the dark for a minimum of 30 minutes. After incubation, red blood cells were lysed, samples were mixed, and incubated at room temperature in the dark for an additional 10 minutes. Plates were centrifuged and the supernatant was decanted. Cell pellets were then resuspended in 1,800 μL staining buffer, samples were mixed, centrifuged, and the supernatant was decanted. Cell pellets were resuspended in 500 μL staining buffer containing fetal bovine serum, and approximately 300 μL of cell suspension was transferred to a 96-well V-bottom plate for analysis. NK cell percentages, as well as total T and B cell percentages, were applied to cell counts obtained in TruCount™ tubes (BD Biosciences, San Jose, Calif.) and used to determine absolute cell numbers for each cell population. In studies 1-4, CD38+ NK, B, and T cell subsets were assessed at baseline using the anti-CD38 antibodies AB79 or Ab19 as indicated (Figure 1). Although TSF-19 binds to a different epitope, the results were very similar and therefore are not presented separately. Processed samples were analyzed immediately.
[0289] PK model development During PK model development, one-, two-, and three-compartment model structures were explored. The two-compartment model was clearly superior to the one-compartment model as judged by the goodness-of-fit (GOF) plots and the reduction in objective function value (OFV). Based on visual inspection of the diagnostic plots, the introduction of a third compartment was not necessary to adequately describe the data. Bioavailability (F) was modeled using a logit transformation, F = exp(PAR) / (1 + exp(PAR)), where PAR represents the model parameter, to ensure that estimates were bounded between 0 and 1. Nonlinear PK at low concentrations was modeled by a quasi-steady-state (QSS) approximation model of the target-mediated pharmacokinetic (TMDD) process (Gibiansky and Gibiansky (2009) Expert Opin. Drug Metab. Toxicol. 5:803-812).
[0290] A schematic of the model is provided in FIG. 3C. For the QSS approximation, we assume that the steady-state concentrations of free drug C, target R, and drug-target complex RC are established very quickly compared to all other processes. This implies that the binding process is balanced with the dissociation and internalization processes, and that the following equation applies with the appropriate units: K ON *C*R=(K OFF +K INT )*RC(where K ON is the binding rate constant, K OFF is the dissociation rate constant, K INT represents the internalization rate constant).
[0291] Intersubject variability (BSV) was investigated for all parameters and modeled by the following type of exponential model: PAR i =TVPAR*e ETAPAR i (In the formula, PAR i are the individual, TVPAR is the typical parameter estimate, and ETAPAR i is the estimate of the deviation for individual i). iValues were assumed to follow a normal distribution with mean zero. Residuals were described by additive and proportional compound error models (Beal and Sheiner (1992) NONMEM User Guides, in University of California CA).
[0292] To identify potential covariate effects on the PK of AB79, the following parameters were examined: body weight, sex, dose, route of administration, and study.
[0293] PK-PD model development PK-PD model development was performed separately for each of the three cell types. Note that measurements close to drug administration (<8 hours post-dose) were not utilized for model development because they were affected by non-specific drug-independent effects, likely due to multiple blood samples taken over a short period of time (Figure 4). The PK model and parameter estimates were fixed. Various forms of turnover, transit compartment, and direct response models were tested (Friberg et al. (2002) J. Clin. Oncol. 20:4713-4721, Mager et al. (2003) Drug Metab. Dispos. 31:510-518). In the turnover models, drug effects were introduced on the cell elimination rate in the form of an Emax type model with or without the Hill coefficient. In the notation here, the Emax model is a function f of drug concentration c of the following form: f(c)=EMAX*c H / (c H +C50 H ) (EMAX is the maximum effect, C50 is the concentration at which half the maximum effect is achieved, and H is the Hill coefficient). In the transit compartment model (TCM), drug effects were introduced and tested for different locations, namely proliferation rate, circulating cells, and a third transit compartment. We also tested the combination of these effects and whether the data supported the existence of a feedback mechanism from circulation to proliferation rate. Additionally, Emax type direct response models with and without the Hill coefficient were tested to describe the drug concentration-effect curves.
[0294] Random effect parameters were introduced to estimate inter-subject variability for baseline cell count, cell generation rate (KIN), transit time (MTT), C50, and EMAX in the transit compartment model. The individual mean baseline cell levels were provided in the data set (column BL), which were used as the representative values in the model. Random effect parameters were added to allow adjustment of individual baseline estimates based on all measurements of the individual. PD residuals were described by a proportional error model.
[0295] For model validation during the modeling process (PK and PK-PD), OFV, standard error, GOF plots, and individual prediction versus data plots were used to assess the models and compare them with alternative models.
[0296] The following software packages were utilized: NONMEM (version 7.2), KIWI (version 1.6), Berkeley Madonna (version 8.3.14), PSN (version 4), and R (version 3.3.0).
[0297] Dataset preparation Data sets from the eight monkey studies were collected, reorganized in a single format, and merged into three separate NONMEM-readable PK-PD datasets. Each of the three datasets contained monkey individual characteristics (study, ID, group, weight, sex), dosing information, PK, and either NK, B, or T cell data. only cell counts were added to the data set, but no PK data, implicitly assuming no serum levels of AB79. Time-resolved information on anti-drug immunogenicity status (ADA), i.e., TITER, which contains the quantitative measurement, and a 0 / 1 flag variable ADAF (ADAF=1 if ADA affects the concentration of AB79, otherwise ADAF=0), were added to each observation in a separate column. ADA titers were measured with different method specifications in different studies, so values cannot be directly compared quantitatively between studies. To utilize ADA information in a consistent manner across all studies, the following procedure was applied separately for each animal: ADA titers that increased above the initially measured level at time points after 7 days were considered ADA positive and flagged in the data set (ADAF=1). If a sample was flagged as ADA positive at one time point, all samples taken after that time point in this animal were also flagged as ADA positive, regardless of the titer measured. ADA positive observations were not used for parameter estimation during model development. Note that PD measurements from sampling time points of PK concentrations affected by ADA were also flagged with ADAF=1.
[0298] For cell count data, individual baseline values for each cell type (NK cells, B cells, and T cells) were calculated as the average of all available pre-dose measurements for a given animal. In most studies, this was a single measurement. The baseline value for each animal was then added to each observation for each animal as the observation at the first dosing event (time=0) and as a constant value in column BL. Based on this baseline value, the percent of baseline for each observed cell count was calculated and added to the data set.
[0299] Scaling of monkey PK parameters The final PK and PK-PD models were used as a starting point to simulate the PK and PK-PD profiles for first-in-human clinical trials. A comparative analysis of data from a therapeutic monoclonal antibody has shown that PK parameters derived from monkey studies can be scaled to predict the human PK profile with acceptable accuracy (Han and Zhou (2011) Ther. Deliv. 2:359-368). The same publication showed that a fixed exponent of 0.85 can be used to reliably predict the human clearance of a monoclonal antibody. Therefore, this relationship was applied to scale the human clearance parameters (CL, Q), while the volume parameters (VC, VP) were scaled using a direct relationship between body weight (BW).
number
[0300] result Pharmacokinetics of AB79 The PK data set was pooled from all eight studies in healthy monkeys excluding the placebo group (Table 3). In total, the set contained data from 140 animals, of which 58 were males and 82 were females. The body weights of the animals studied ranged from 2.1 to 4.7 kg, and the doses ranged from 0.03 to 100 mg per kilogram of body weight (mg / kg). In one group in Study 7 and three groups in Study 8, doses of 0.03, 0.1, 0.3, and 1 mg / kg were administered SC (total of 15 animals). The pooled data set The study included 2,199 measurable PK observations above the LLOQ (Figure 3A,B). ADA was assessed in parallel with AB79 concentration. 229 PK observations were found to be affected by ADA (Figure 5). PK was most densely sampled after the first dose, and even in the long-term toxicology study, most animals were terminated before day 98. Only Study 4 included a recovery group, and we were only able to collect PK data from four animals, two from the 80 mg / kg group and one each from the 30 mg / kg and 3 mg / kg groups (Figure 3B).
[0301] First, PK analysis was performed using standard noncompartmental techniques (NCA) for each of the monkey studies. Based on single-dose studies (IV bolus injection or 30-minute IV infusion), the volume of distribution during the terminal phase (Vz) was calculated to range from 64 to 116 mL / kg, the clearance from 6.04 to 14.7 mL / kg / day, and the terminal elimination half-life (T1 / 2) from 4.75 to 11.2 days. Area under the concentration-time curve (AUC) and maximum concentration (Cmax) values were found to increase proportionally with dose over a wide range. Only the lowest dose group PK profile (<1 mg / kg, Figure 3 D-F) provides evidence of nonlinearly increasing clearance at concentrations below 0.5 μg / mL, possibly caused by a target-mediated drug delivery mechanism (TMDD) (Kamath (2016) Drug Discov. Today Technol. 21-22:75-83). A linear two-compartment model was constructed based on data from all monkey studies except for the two lowest dose groups (doses >0.3 mg / kg). When the PK of the lowest dose groups was simulated and overlaid with the measured concentrations, it was apparent that the linear model overpredicted the concentrations (Figure 3D-F).
[0302] Available PK data after single-dose SC administration revealed that Cmax was 70-80% lower in the SC group versus the IV group at the same dose, and AUC was similar. No differences in PK parameters were observed between male and female monkeys. The results of these initial analyses were used as the starting point for model development.
[0303] PK model development Model development began with single IV dose data and then more complex data were utilized to gradually extend the initial model. Similar to other therapeutic antibodies, the PK generally follows a linear two-compartment model (Kamath (2016) Drug Discov. Today Technol. 21-22:75-83). The nonlinear elimination component (TMDD), describing the accelerated clearance at low concentrations, was modeled by the quasi-steady state (QSS) approximation (Gibiansky and Gibiansky (2009) Expert Opin. Drug Metab. Toxicol. 5:803-812). The assumption that the drug-target association process is much faster than the processes of drug dissociation, distribution, and elimination, and the elimination of the target and drug-target complexes, leads to a simplified TMDD model (Figure 3, Table 4). The amount of data at low concentrations was relatively small, and as a result, not all parameters were estimated in a single estimation run of the software program. Therefore, the parameters of the TMDD model were first estimated by focusing on the data of low-dose single-dose studies 7 and 8. The resulting TMDD parameter estimates were then kept fixed during the final estimation for the entire data set (Table 4).
[0304] [Table 4]
[0305] Absorption parameter K A Estimates of F and F were obtained when adding the data for the SC groups. All SC data were from the four lower single-dose groups from Studies 7 and 8. These lower doses (≦1 mg / kg) encompassed the clinically relevant range but may limit the generalizability of the parameter estimates to higher doses.
[0306] The intersubject variability (BSV) of PK parameters was described by an exponential model. A ), clearance (CL), and peripheral volume of distribution (V P ) has an estimated BSV of approximately 40% and a median distribution volume (V C ) had an estimated BSV of approximately 20% (Table 4). Covariate analysis revealed that V C The effect of route of administration on V CTypical values for were 0.141 L when administered IV and 0.043 L when administered SC (approximately 70% smaller). No other significant covariate effects were identified. Due to the limited amount of data at low concentrations, intersubject variability and individual prediction of TMDD parameters were estimated based on the internalization rate K INT The BSV was estimated only for AB79 (BSV: 49%). Model evaluation based on the residual error, OFV, standard error, GOF plots, and individual curve fits confirmed that the final model adequately described the PK of AB79 in healthy monkeys (Table 4, Figure 6).
[0307] Pharmacodynamics The levels of AB79 binding on human and monkey blood NK cells, T cells, and B cells were compared by flow cytometry analysis. As shown in Figure 7, monkey lymphocytes had slightly lower CD38 expression levels compared to their human counterparts based on the number of molecules of fluorescence (MOEF) that exhibit the same amount of fluorescence intensity of AB79, but the relationship between cell types was similar, e.g., CD38 expression was NK cells > B cells > T cells. These data support the use of this non-human primate species as a meaningful model to help predict the potential of AB79 for PD activity in humans.
[0308] For detailed quantitative analysis of the relationship between drug exposure (PK) and the extent and duration of cell depletion (PD), data sets from all eight monkey studies, including placebo-treated animals, where available, for PK concentrations, NK cell, B cell, and T cell counts were compiled (Table 3). Initial characterization of the data sets showed that at baseline, T cells were the most abundant lymphocyte subtype with a median of 3,732 cells per μL (interquartile range (IQR): 2,881–5,176), compared with B cells with 1,279 cells per μL (IQR: 860.8–1,890) and NK cells with 685 cells per μL (IQR: 482.8–970.1). Baseline CD38 expression on these cell populations was assessed in studies 1–4 (Table 3, n=67). 86.7% (SD 11.3) of NK cells expressed CD38, with less variation. In contrast, 58.7% (SD 27.0) of B cells and 34.5% (SD 24.5) of T cells expressed CD38, with greater variability.
[0309] Data from placebo-treated animals showed that the mean numbers of each of the cell types varied over time between individual animals beyond what would be expected from variability within one individual (Figure 8). For example, the mean coefficient of variation for B cell counts in individual placebo curves was 27%, while individual mean B cell levels ranged from 436.6 to 4,389. Additionally, differences also existed between male and female animals, as well as between mean baseline lymphocyte counts from animals in different studies, increasing variability (Figure 9). Based on these results, each cell count after treatment was calculated at each time point relative to its individual baseline value in percent rather than absolute cell counts. For example, a value of 33% means that the cell count was 1 / 3 of the baseline cell count in the sample. This provided standardized values that were comparable across the entire data set.
[0310] The rapid onset of depletion of AB79-bound cells suggests that initial blood concentrations drive the decline in lymphocyte counts (Figure 10). With an IV dose of 0.3 mg / kg AB79, the median maximal effect on NK cells was 93.9% depletion (i.e., 6.1% of baseline cell counts remaining). At 0.1 mg / kg, peak depletion was 71% (29% of baseline remaining). At doses >0.3 mg / kg, NK cells were nearly completely depleted in the blood compartment (nadir (range), 1.06% (0.17, 6.23) of baseline, Figure 10A). After a single dose of 0.3 mg / kg, it took approximately 7 days for NK cells to recover to a mean of 50% of baseline, although the kinetics of recovery varied widely between individuals (Figure 10B,C). Consistent with these results, NK function was also tested in a subset of animals in Study 7 (n=3 / group, Table 3). This experiment showed a dose-dependent reduction, with minimal change in blood NK activity at 48 hours post-treatment in animals treated with 0.1 mg / kg AB79 (% lysis at 100:1 effector:target ratio ±SD; 44.5% ±23.6% vs. 41.4% ±25.8%), and a near complete loss of NK activity in animals treated with 1.0 mg / kg (% lysis at 100:1 effector:target ratio ±SD; 37.4% ±10.3% vs. 6.8% ±12.5%). NK cell function showed recovery at 57 days, the next time point measured (% lysis at 100:1 effector:target ratio ±SD; 16.0% ±11.9%).
[0311] B and T cells were depleted to a lesser extent compared with NK cells, which may be due to their This is consistent with lower CD38 expression levels (Figure 7). For example, at 0.3 mg / kg AB79 IV, B cells had a median maximum depletion level of 45% of baseline, and T cells were depleted to 43% of baseline (Figure 10D,G). At this dose level, a 50% reduction from baseline in B cell numbers was not achieved in all animals. Only at the highest dose of ≥30 mg / kg were B cells nearly completely depleted (Figure 10D). T cells were depleted to a similar extent as B cells, but recovery was more rapid (Figure 10G-I).
[0312] In two studies 7 and 8, IV and SC dosing (FIG. 10C, F, I) were compared. There were no obvious differences in cell depletion between routes of administration. At the lower dose (study 8), persistent (>24 hours) cell depletion below 50% baseline values was seen only in the NK cell population, but not in T and B cells, although all cells showed some cell depletion at early time points. The time of onset of NK cell depletion appeared to be similar between dose groups regardless of route of administration, and the duration of depletion was dose-dependent. Cell recovery in all test groups was seen by day 57.
[0313] PK-PD model Separate PK-PD models were developed to describe the effect of AB79 exposure on NK cells, B cells, and T cells. During PK-PD modeling, PK parameters were kept fixed at the estimates of the final PK model, and various PD models were tried (see Materials and Methods for details). The NK cell population in peripheral blood was well described by a turnover model, and the depleting drug effect was related to the depletion rate via PK concentration by an Emax type model. In this model, EMAX represents the maximum rate of additional NK cell depletion, and C50 represents the concentration at which the rate of additional NK cell depletion is half-maximal. The structural PK-PD model of NK cells is of the following form:
number
[0314] where NK is the actual number of NK cells, K IN is the production rate, K OUT represents the rate of elimination in the absence of drug. At a given baseline measurement, BL OUT is the equation K OUT =K INNote that the parameters are defined by KIN, EMAX, and C50. c represents the AB79 concentration in the central compartment. When all parameters were estimated at once, the software program did not produce stable results. The individual estimates of KIN, EMAX, and C50 were highly correlated. Moreover, due to the limited distinction between the maximum effects of different doses (see previous section) and the large inter-individual variability, accurate estimates of all parameters could not be expected. In a series of estimations, one or two of the three parameters KIN, EMAX, and C50 were fixed to different values and the others were estimated. Stable performance and a reasonable goodness of fit were achieved with KIN fixed at 10,000 and EMAX at 322. A typical C50 estimate was 29.0 μg / mL (Table 5). Additionally, the sensitivity of the selected KIN and EMAX values was tested by choosing different combinations of higher and lower values. The inter-subject variability was estimated by the NK production rate K IN The C50 was 113% and C50 was 149%, consistent with the high individual variability at baseline and between treated animals. The model was evaluated based on the residual error, OFV, standard error, GOF plots, and individual curve fits (Table 5, Figure 4).
[0315] [Table 5]
[0316] The transit compartment model was superior to the direct response or turnover models for describing AB79-induced B cell depletion. A four-transit compartment was found to be sufficient, and drug effects were described by an Emax-type model for the depletion rate. Similar to the NK cell depletion model, EMAX represents the maximum rate and C50 represents the concentration at which the rate is half-maximal. Thus, the structural PK-PD model for B cells is given by the following five equations:
number
number
number
[0317] TR i (i=1-4) represents the four passage compartments. K TR , K PROL , and K CIRC is expressed by the following equation K TR =K PROL =K CIRC = 4 / MTT, where MTT means transit time (Friberg et al. (2002) J. Clin. Oncol. 20:4713-4721). B represents the number of B cells in the blood, and c represents the AB79 concentration in the central compartment.
[0318] With an EMAX fixed at 2.37, the typical C50 was 19.5 μg / mL and the typical mean transit time (MTT) was 8.48 days (Table 5). The delay in maximum effect relative to maximum AB79 concentration was well captured. This model indicates that AB79 primarily affects circulating B cells. No additional effects on progenitor cells and feedback loops were necessary to describe the available monkey B cell data. The intersubject variability of 135% for MTT and 24.1% for baseline B cell levels (BASE) indicates high individual variation between animals.
[0319] Drug-induced depletion of T cells with rapid recovery was well described by the following direct response model: T(c)=BL T *(1-EMAX*c / (c+C50)) (where T represents the actual T cell count and BL T(c represents the T cell count at baseline and c represents the AB79 concentration in the central compartment). A typical C50 was estimated to be 11.86 μg / mL, and a typical EMAX was 0.47, indicating that in this example, only about half of the T cells can be depleted by AB79 (Table 5). Note, however, that the intersubject variability for EMAX was close to 70%. In this model, unlike the NK and B cell depletion models, C50 represents the concentration at which T cell depletion was half-maximal.
[0320] As for NK cells, model evaluation of the final PK-PD models for B and T cells based on residual error, OFV, standard error, GOF plots, and individual curve fits supported that they adequately described the available monkey data (Table 5, Figure 4).
[0321] Simulation of human PK and cell depletion The monkey PK and PK-PD models were used as a starting point for model-based simulations of human PK and cell count data to support the design and justify the selected doses for first-in-human (FIH) clinical trials in healthy volunteers. To this end, it was assumed that the model structure, including the TMDD derived from the monkey data, also describes the main features of human PK and the resulting lymphocyte depletion. To obtain predictions for human PK parameters, estimates of the following monkey PK parameters were scaled: central and peripheral volumes of distribution (V) using a straightforward approach for monoclonal antibodies. C , V P ), as well as clearance (CL) and intercompartmental clearance (Q) (Han and Zhou (2011) Ther. Deliv. 2:359-368). Because AB79 is a fully human monoclonal antibody, its immunogenicity in humans is expected to be lower than that observed in monkeys. Therefore, for modeling and simulation, ADA-positive samples were excluded from the data set.
[0322] The scaled model was used to simulate the exposure dose, as well as the NK cell, B cell, and T cell depletion profiles for single doses of 0.0003 to 1.0 mg / kg via 2-hour infusion (IV) or subcutaneous injection (SC) as planned in the FIH study (Figure 11). Simulations showed that after an IV dose of 0.0003 mg / kg, Any observable drug-induced effect on NK cell counts and even measurable PK concentrations above the LLOQ would not be expected. Due to variability and limited size of dose groups, it was assumed that the minimal detectable drug effect on NK cell counts would be at least a 10% reduction. It was predicted that doses of 0.01 mg / kg IV and 0.03 mg / kg SC would deplete NK cells to less than 90% remaining of baseline.
[0323] At 0.3 mg / kg IV dosing, NK cells were predicted to be depleted to a remaining 17% of baseline within 3 hours after the end of the infusion, recovering to over 50% after 11 days (Figure 11). At the same dose, the model predicts that B cells would be maximally depleted to 67% of baseline after 2.5 days, and T cells would be immediately depleted to 86% of baseline. For the same 0.3 mg / kg dose administered subcutaneously, the model predicted that it would result in less and later maximal depletion (nadir compared to baseline: NK cells 37%, B cells 74%, T cells 94%).
[0324] These in vitro and in vivo preclinical studies demonstrate that monkeys are a suitable animal model to study the pharmacology of AB79. Densely sampled PK and cell count data of NK, B, and T lymphocytes from eight monkey studies with diverse doses and dosing regimens provide a rich source of data for a comprehensive and quantitative understanding of the relationship between AB79 dose, exposure, and cell depletion. The population PK and PK-PD models generated provide a powerful tool to fully describe the observed data and predict exposure and lymphodepletion not only for future studies in monkeys, but also for clinical trials in human subjects.
[0325] A first-in-human (FIH) single ascending dose study in healthy volunteers was conducted (www.clinicaltrials.gov:NCT02219256) (Figure 12). The intended pharmacological effect of AB79 is depletion of activated lymphocytes. However, significant and sustained depletion of lymphocytes (enhanced pharmacology) may lead to immune system impairment, which would be intolerable to patients or healthy study participants. Therefore, a safe IV starting dose of 0.0003 mg / kg was selected for the FIH study.
[0326] Monkey data suggested that NK cell depletion was determined to be the most sensitive biological effect. PK-NK simulation results helped determine the minimum dose level of 0.01 mg / kg IV at which the most sensitive pharmacological effect (NK cell depletion) was predicted to be detectable in humans. Emerging data from FIH studies revealed that the overall pattern of dose-dependent and cell type-specific depleting effects of AB79 is consistent with model-based predictions (manuscript in preparation). AB79 appears to be even more efficient than predicted. For example, at 0.03 mg / kg IV dosing, NK cells in human subjects were depleted to the point where less than 10% of baseline remained. The median nadir (lowest depletion point) in monkeys at this dose was 20.0% (Figure 10).
[0327] Three cytolytic anti-CD38 monoclonal antibodies (daratumumab, isatuximab, and MOR202) are in clinical development for multiple myeloma (van de Donk et al. (2016) Immunol. Rev. 270:95-112). Daratumumab (Darzalex™, given as an intravenous infusion) was recently approved for multiple myeloma in the United States and for non-Hodgkin's lymphoma in Europe. Unlike AB79, daratumumab does not cross-react with monkey CD38. Therefore, comparison of the results with AB79 in cynomolgus monkeys here with daratumumab was not possible. Moreover, patients with multiple myeloma have high levels of CD38-positive malignant cells, which may require higher effective antibody concentrations for this cancer indication. (de Weers et al. (2011) J. Immunol. 186:1840-18 48).
[0328] However, it is noteworthy that daratumumab is approved in multiple myeloma at weekly IV dosing of 16 mg / kg, even though AB79 achieved complete depletion of peripheral NK cells at approximately 1 mg / kg and complete depletion of B cells at approximately 3 mg / kg (Figure 10).
[0329] Despite the extensive database from eight monkey studies, several limitations were recognized. AB79 effectively depletes NK cells even at 0.03 mg / kg, the lowest dose studied. At such low doses, PK rapidly declined below the limit of quantification of the bioanalytical assay, which prevented elucidation of the exposure-effect relationship at lower doses. Moreover, during preclinical development, it was recognized that maximum cell depletion occurs shortly after maximum drug concentration, but elucidation of the early stages of depletion is technically limited by the overall sample number and, potentially, nonspecific cell depletion due to repeated blood draws (blood draw effect). The blood draw effect was observed as a transient pancytopenia characterized by depletion of cell types that do not bind AB79 and was not dose-dependent, suggesting that it is due to loss of blood volume as a result of multiple blood draws rather than any specific effect of AB79 (Figure 13). As a result, the ability to accurately estimate model parameters, particularly with respect to NK cell depletion, was limited, and typical values of KIN and EMAX required fixation to achieve stable and sufficient estimation results.
[0330] The effect of AB79 on tissue plasma cells or plasmablasts could not be measured. However, like plasma cells and plasmablasts, NK cells have high levels of CD38 on their surface, and the efficiency of cell depletion of certain lymphocyte subsets depends at least in part on the expression level of CD38. Therefore, the cytolytic effect of AB79 on plasmablasts and plasma cells may be comparable to that on NK cells. Currently, there is limited information on the long-term effects of AB79 treatment in monkeys. Only a small subset of animals in the 13-week toxicology study was investigated for a longer period in the recovery group, and most of the animals in all dose groups developed ADA. Moreover, the baseline values and depletion profiles of different lymphocyte subsets were highly variable between individuals. Therefore, the long-term effects of AB79 cannot be investigated in monkeys and will need to be studied in humans.
[0331] With the emergence of new human data, it will be interesting to compare human and monkey PK and PD data in detail. Building a PK model based on human data and comparing it with monkey models will allow for the refinement of the TMDD model of AB79. Data generated from studies in patients will provide insight into how AB79-mediated depletion of B-lineage cells compares between RA and SLE patients, as well as between multiple myeloma and healthy subjects. In addition to CD38 expression levels, investigation of subject or disease-related factors that may affect cell depletion efficiency is also important and may lead to individualization of treatment. Additionally, thorough in vitro and in vivo head-to-head comparison of AB79 with daratumumab and / or other CD38 antibodies will reveal valuable information about the pharmacology of anti-CD38 antibodies and their optimal applications.
[0332] Extensive pharmacological data as well as PK and PK-PD models allowed characterization of exposure-effect relationships in cynomolgus monkeys. Model-based analysis of NK, B, and T cells supported and quantified the findings that each of the blood lymphocyte subsets is depleted by antibodies at different rates and requires different periods to refill the blood compartment. These models proved to be excellent tools to simulate PK and PD data under different dosing scenarios in preparation for clinical trials.
[0333] Example 2: CD38+ cell depletion with AB79 CD38 is a cADPR hydrolase expressed on human plasmablasts, plasma cells, NK cells, and activated T and B cells, based on AB79 binding, but not on mature platelets or erythrocytes. In patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), plasma cells, as well as activated B and T cells, may be important causative agents of the disease. Targets CD20 and inhibits CD20. 低 / 陰性Unlike other B cell selective therapies that do not directly deplete plasmablasts, CD38 is expressed at high levels on plasmablasts and plasma cells, making these cells a direct target of AB79. In vitro studies with human blood cells and cell lines show that binding of AB79 to CD38 does not result in cytokine activation in PBMCs, demonstrating that AB79 is not an agonist as discussed below. Rather, AB79 mediated cell depletion of human B lineage cell lines by ADCC and CDC, and in most instances, cell lines with increased CD38 expression were more susceptible to cell lysis (Figure 14). This is consistent with findings in healthy cynomolgus monkeys, where the efficiency of depletion correlated with CD38 expression levels and AB79 dose levels. NK cells expressing high levels of CD38 were depleted to a greater extent than CD20+ B cells and CD3+ T cells, which express less CD38 (Figure 15). In vivo, AB79 potently suppressed human B cell recall responses to antigen in a mouse adoptive transfer model (Figure 16). Collectively, these data support further investigation of AB79 in autoimmune disease.
[0334] Human PBMCs were treated with AB79 under multiple conditions and inflammatory cytokine release was measured. Cynomolgus monkeys were used to demonstrate cell type specific depletion and the relationship between AB79 dose, as AB79 cross-reacts with monkey CD38, which shares 91% protein identity to the human protein. A second animal model, adoptively transferred human PBMCs in mice, was used to determine whether AB79 could target human antibody-producing cells.
[0335] AB79 binds to CD38 and mediates ADCC and CDC Receptor counts were determined using a mouse anti-human CD38 antibody (clone HIT2) with an FI kit (DAKO, catalog number K0078) and calculated by converting the mean fluorescence intensity (MFI) of the stained samples to a standard curve generated from the MFI of five bead populations with a defined number of antibody molecules bound to them. Absolute receptor counts were calculated by subtracting the MFI of the isotype control (mouse IgG1) from the MFI of the anti-CD38 antibody.
[0336] CDC was assessed by plating cell lines at 10,000 cells / well and adding AB79, control IgG, or media. A 5-point dose-response curve (0.001-10 mg / ml) was typically performed. Rabbit complement (2-15 ul, no. CL 3441 CedarLane Laboratories) was added to each well except for the control wells. CytoTox-Glo reagent (Promega, G7571 / G7573) was used to detect cytotoxicity by luminescence. Groups tested: cells alone, cells + complement, cells + IgG control + complement, cells + AB79 + complement. CDC% equation: CDC%=100-((RLU(test) / RLU(complement alone))×100).
[0337] ADCC was tested by plating 5000 target cells / well (T, cell line) with 50ml of AB79, control IgG, Triton X-100 (1%, Sigma Chemical), or media alone and 50ml of human effector (E) PBMCs at a ratio of 1:25 to 1:50 T:E cells. A 9-point antibody dose-response curve (0.000001-100 nM) was typically performed. Experimental lysis = PBMC + cell line + antibody. Spontaneous lysis = PBMC + cell line without antibody. Maximum lysis = cell line + Triton X-100. Cytotoxicity was assessed using the CytoTox-Glo™ luminescent cytotoxicity assay (Promega).
[0338] AB79 has no agonist activity The ability of AB79 treatment to induce cytokine production in human PBMC was compared to a negative IgG1 isotype control and positive controls PHA, anti-CD3 (clone OKT3), or anti-CD52 (Campath) antibodies.
[0339] Soluble AB79 did not increase IL-6 levels (mean ± SD) in PBMCs collected from four different subjects after 24 hours of incubation compared to IgG1 isotype control. PHA increased cytokine levels in all subjects, demonstrating that the cells have the ability to produce IL-6. Similar results were seen in PBMCs stimulated for 48 hours, as well as when IL-2, IL-4, IL-10, GM-CSF, IFNγ, and TNFα were tested (data not shown) (Figure 18).
[0340] The way in which an antibody is presented to cells can contribute to the antibody's performance, i.e., ligand binding and cellular response (Stebbings et al. (2007) J. Immunol. 179:3325-3331). Stebbings et al. showed that the greatest cellular response (cytokine release) to agonist antibodies occurred when the antibody was highly concentrated and attached to the well surface, compared to antibodies that were added to the well in solution and the liquid was evaporated (dry-bound), bound to the well in solution (wet-bound), or added directly to PBMCs (soluble) (Figure 18A). AB79 did not stimulate cytokine production using any of these approaches (Figure 18B).
[0341] AB79 (100 mg / ml) did not stimulate IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFNγ, or TNFα after 24 hours under any of the conditions tested. AB79 did not induce IL-10 or GM-CSF, both of which were induced by anti-CD3 (not shown, all values except anti-CD3 are below the LLOQ). IL-8 was constitutively produced by PBMC and was not altered by any of the treatments (data not shown) (Table 6).
[0342] [Table 6]
[0343] AB79 depletes CD38+ cells AB79 binds CD38 with high affinity and mediates CDC and ADCC. AB79 is not an agonist and did not induce cytokine release from human PBMCs. AB79 bound to CD38 from both humans and cynomolgus monkeys. Lymphocytes from both species had similar cell-specific CD38 expression patterns based on median fluorescence intensity of AB79 staining: NK cells > B cells > T cells. Treatment with AB79 depleted monkey lymphocytes in a reversible, cell-specific, and dose-dependent manner. AB79 effectively blocked human antibody recall responses in a mouse adoptive transfer model.
[0344] In cohorts treated with AB79 by SC injection, there was a dose-dependent reduction in NK cells (Figure 24) and plasmablasts (Figure 25) at doses ≥ 0.1 mg kg -1 was observed at 0.6 mg kg -1 There was a ≥90% reduction in plasmablasts in all subjects receiving 0.6 mg kg -1 (data not shown), of which C max is 23.0ng mL -1 (Table 7). Plasmablast and NK cell levels were reduced from baseline within 8 hours after injection, and the 48 hour t max The time required for recovery to baseline levels varied, with the 0.1, 0.3, and 0.6 mg kg -1 Recovery to baseline for doses (i.e., within -20% of baseline levels) required an average of 4, 78, and 50 days, respectively (data not shown). Minimal or no reductions were observed for total lymphocytes, B and T cells, cytotoxic T cells, helper T cells, monocytes (Figure 25), and granulocytes, red blood cells, and platelets (data not shown).
[0345] [Table 7]
[0346] Summary of AB79 and Daratumumab Erythrocyte Binding The RBC binding profiles of AB79 and daratumumab were compared. As illustrated in Figure 26, there appears to be a difference in the magnitude of RBC binding (i.e., MFI) between the drugs in three of the four donors tested. However, this difference may be due to differences in biotin levels on each of the antibodies, of which daratumumab had 1.6-2.0-fold more biotin than AB79. An alternative analysis to control for potential differences in fluorescent labeling of the antibodies is to compare the concentration vs. binding profile of each antibody, with a useful metric being the concentration at which maximal binding occurs (i.e., maximum specific binding of antigen (Bmax)). Bmax is identical for both antibodies in three of the four donors (e.g., 1 μg / mL for donor 1). Collectively, these data indicate that both antibodies bind with similar affinities within the current resolution limit of the assay, which is 10-fold. In conclusion, both AB79 and daratumumab bound to RBCs with affinities that were within 10-fold of each other in this assay. There was no 10-fold or greater difference in the binding affinity of these antibodies to RBCs within this assay system.
[0347] Example 3: A Phase 1 / 2a Study Investigating the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of AB79 Administered Subcutaneously as a Single Agent in Human Patients with Relapsed / Refractory (r / r) Multiple Myeloma (MM) The objective of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) / recommended dose for phase 2 (RP2D) in participants with relapsed and / or refractory multiple myeloma (RRMM) in phase 1 of the study and to provide a preliminary assessment of clinical activity of AB79 monotherapy. The study will include patients with RRMM who have been previously treated with at least a proteasome inhibitor (PI), an immunomodulatory drug (IMid), an alkylating agent, and a steroid. Patients must have refractory disease or be intolerant to at least one PI and at least one IMiD, and must have received either three or more prior therapies, or at least two prior therapies if one of those therapies included a combination of a PI and an IMiD. Prior exposure to an anti-CD38 agent is permitted but not required in the phase 1b dose escalation portion. In the Phase 2a expansion portion of the study, patients must also have had disease refractory to at least one anti-CD38 monoclonal therapy at any time during treatment. The study is a multicenter trial conducted in the United States that includes approximately 42 participants.
[0348] Phase 1 The Phase 1 study population consisted of approximately 24 adult participants aged 18 years or older. Patient characteristics are shown in Table 8. [Table 8]
[0349] Phase 1 participants will be assigned to one of six escalating dose AB79 treatment arms: Cohort 1: 45 mg, Cohort 2: 135 mg, Cohort 3: 300 mg, Cohort 4: 600 mg, Cohort 5: 1200 mg, and Cohort 6: 1800 mg (Table 9). AB79 will be delivered by subcutaneous injection once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in 28-day treatment cycles until treatment discontinuation due to disease progression (PD), unacceptable toxicity, or other reasons. Participants may receive premedication 1-3 hours prior to administration of AB79 on each dosing day, such as: dexamethasone (20 mg), acetaminophen (650-1000 mg), diphenhydramine (25-50 mg), and montelukast (10 mg).
[0350] [Table 9]
[0351] The total duration of participation in this study is 36 months (3 years). In Phase 1, participants who stop treatment for any other reason other than PD will continue to receive progression-free survival (PFS) follow-up at the site every 4 weeks for up to 12 months from the last dose of study drug or until PD, death, loss to follow-up, withdrawal of consent, or end of the study. Participants will be followed for follow-up assessments for 30 days from the last dose of study drug or until initiation of subsequent alternative anticancer therapy, whichever occurs first.
[0352] Phase 1 Primary Endpoint Metrics Primary endpoint metrics up to one year include: Number of participants reporting one or more treatment-emergent adverse events (TEAEs) Number of participants with dose-limiting toxicities (DLT): A DLT is defined as any of the following events: grade 4 laboratory abnormalities excluding events clearly attributable to external causes; grade 3 nausea / vomiting, fatigue lasting <72 hours, grade 1 or less (≤) elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) that resolves to baseline within 7 days, or non-hematologic TEAEs of grade 3 or greater (≥) excluding infusion reactions (IRs) that respond to symptomatic treatment; National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade ≥4 hematologic TEAEs excluding grade ≥3 hemolysis, platelet count drop or increase with grade 3 clinically significant bleeding; and incomplete recovery from treatment-related toxicity causing a delay of more than 2 weeks (>) of the next scheduled infusion before the start of Cycle 2 will be considered a DLT. Number of participants with Grade 3 or higher TEAEs: AE grades are assessed according to NCI CTCAE, version 4.03: Grade 1 scaled as mild; Grade 2 scaled as moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequence; and Grade 5 scaled as death related to the AE. Number of participants with serious TEAEs Number of participants with TEAEs leading to treatment discontinuation Number of participants with TEAEs leading to dose modifications
[0353] Secondary endpoint measures: Secondary endpoint metrics include: Cmax: maximum observed serum concentration of AB79 [Time Frame: Cycles 1 and 2: pre-dose and multiple post-dose time points (up to 168 hours) on Day 1]. Tmax: time to reach maximum observed serum concentration (Cmax) of AB79 [Time Frame: Cycles 1 and 2: multiple time points (up to 168 hours) pre-dose and post-dose on Day 1]. AUC: Area under the serum concentration-time curve from time 0 to the time of last quantifiable concentration of AB79 [Time Frame: Cycles 1 and 2: Pre-dose and multiple post-dose time points (up to 168 hours) on Day 1]. · Phase 1: ORR [Time Frame: up to 1 year]: ORR is defined as the percentage of participants who achieve a PR of ≥ 50% tumor shrinkage during the study. PR is defined as ≥ 50% reduction in serum M-protein and ≥ 90% or reduction in 24-hour urinary M-protein to < 200mg / 24hr. Percentage of participants with minimal response (MR) [time frame: up to 1 year]: MR is defined as a ≥ 25% but ≤ 49% reduction in serum M-protein and a 50%-89% reduction in 24-hour urinary M-protein. Percentage of participants with positive anti-drug antibodies (ADA) [time frame: up to 1 year].
[0354] result: As of March 5, 2019, 19 patients have been enrolled across four dosing cohorts (45 mg, 135 mg, 300 mg, and 600 mg) and have received at least one cycle of AB79. As of March 5, 2019, nine patients remain monitored on treatment, nine patients have discontinued AB79 due to disease progression, and one patient has withdrawn consent.
[0355] As of March 5, 2019, no dose-limiting toxicities (DLTs) have been reported in DLT-evaluable patients across all four cohorts (45 mg, 135 mg, 300 mg, and 600 mg). No adverse events were reported. There were no injection site reactions or systemic infusion reactions. No drug-related SAEs, on-study deaths, or AEs leading to study discontinuation were reported (see Table 10). In addition, there were no notable laboratory findings, except for one grade 3 transient treatment-related neutropenic event and one transient anemia. Disease progression in one patient was associated with grade 3 thrombocytopenia, anemia, and increased creatinine. The study is ongoing and patients continue to be followed.
[0356] [Table 10]
[0357] As of March 5, 2019, the most common TEAEs (in >2 patients) by preferred term of any causality across all four cohorts were anemia (n=7 patients), insomnia (n=5 patients each), upper respiratory tract infection, dizziness, headache, and hypertension (n=4 patients each), as well as diarrhea, fatigue, decreased appetite, and muscle spasms (n=3 patients each). All AEs were grade 1 or 2, except for anemia (n=2 patients), diarrhea, decreased platelet count, decreased neutropenia, increased creatinine, headache, hypertension, and musculoskeletal pain (n=1 patient each), which were grade 3. Only one event of decreased neutrophil count and one event of anemia were reported as related to the study drug. No cases of IRR, cytokine release syndrome, or injection site reactions were observed. Thus, the present invention provides a therapeutic approach that is safer in clinical use than previous anti-CD38 antibodies such as daratumumab, isatuximab, or MOR202. The present invention provides a novel anti-CD38 antibody.
[0358] FIG. 20 shows that exposure of subcutaneously administered Ab79 increased with increasing dose over time, consistent with target-mediated drug clearance.
[0359] Subcutaneously administered Ab79 reduced levels of plasmablasts in blood (Figure 21), plasmablasts in bone marrow aspirate (Figure 22), and plasma cells in bone marrow aspirate (Figure 23) in a dose-dependent manner. CD38 was saturated on target cells in peripheral blood at doses of ≥45 mg weekly and on target cells in bone marrow at doses ≥300 mg weekly. Target cell levels in bone marrow and peripheral blood were reduced in a dose-dependent manner at doses ≤300 mg weekly.
[0360] In patients with advanced RRMM, AB79 has shown early signs of antitumor activity, as evidenced by at least a 50% reduction in disease burden in some patients and long-term disease stabilization in others. Although additional data are needed to characterize the clinical benefit of this agent, emerging data support the continued development of AB79.
[0361] Two CD38 mAbs are currently in clinical development, of which intravenous daratumumab is approved for patients with MM (relapsed and newly diagnosed) and intravenous isatuximab is under investigation. The most frequent adverse events (≥20%) with daratumumab monotherapy or in combination with standard antimyeloma regimens are infusion-related reactions (IRR), neutropenia, thrombocytopenia, fatigue, nausea, diarrhea, constipation, vomiting, muscle spasms, arthralgia, back pain, fever, chills, dizziness, insomnia, cough, dyspnea, peripheral edema, peripheral sensory neuropathy, and upper respiratory tract infection (Darzalex USPI). Daratumumab can cause severe and / or serious infusion reactions, including anaphylactic reactions, which have been reported in approximately half of all patients (Darzalex USPI). Attention must also be paid to the interference of daratumumab with certain clinical laboratory assays, which may importantly complicate blood compatibility testing (Darzalex USPI). Isatuximab, a humanized anti-CD38 monoclonal antibody, has also been investigated in multiple myeloma. AEs reported with isatuximab (≧24%) included infusion reactions, nausea, fatigue, dyspnea, and cough, which were typically grade ≦2 (Richter et al. (2016) JCO 34(15):8005, Dimopoulos et al. (2018) Blood 132(suppl.1):ASH abstract 155 / oral presentation)). Thus, based on the available evidence, there remains a need for new agents, including a new generation of CD-38 targeted therapies, with greater selectivity and therefore greater efficacy, resulting in less toxicity and improved patient convenience, to continue to improve clinical outcomes.
[0362] Phase 2 The Phase 2a study population will consist of approximately 18 participants. Phase 2a dosing and premedication will be based on a review of available safety, efficacy, PK, and pharmacodynamic data from the preceding Phase 1 cohort.
[0363] [Table 11]
[0364] Phase 2a Primary Endpoint Metrics Primary endpoint metrics up to one year include: Overall Response Rate (ORR): ORR is defined as the percentage of participants who achieved a partial response (PR) of 50 percent (%) or greater tumor shrinkage during the study. PR is defined as a ≥ 50% reduction in serum M-protein and a ≥ 90% or reduction in 24-hour urinary M-protein to less than (<) 200 milligrams (mg / kg) per 24 hours.
[0365] Phase 2a Secondary Endpoint Metrics Secondary endpoint metrics up to one year include: Phase 2a: Number of participants with DLT Phase 2a: Number of participants reporting one or more TEAEs Phase 2a: Number of participants with TEAEs leading to dose modification Phase 2a: Number of participants with TEAEs leading to treatment discontinuation Phase 2a: Number of participants with clinically significant laboratory values Phase 2a: Number of participants with clinically significant vital sign measurements Phase 2a: Duration of Response (DOR): DOR is the time from the date of first reported response to the date of first reported PD. PD is a ≥ 25% increase from the lowest response in any of the following: serum M-protein (increase must be ≥ 0.5 g / dL. If baseline M-protein is ≥ 5 g / dL, an increase in serum M-protein of ≥ 1 g / dL is sufficient to define relapse), and / or urinary M-protein (increase must be ≥ 200 mg / 24 hr), and / or abnormal / uninvolved only in participants without measurable serum and / or urinary M-protein levels. ved) difference between free light chain (FLC) levels (increase must be >10 mg / dL) and, only in participants without measurable serum and / or urinary M-protein levels and without disease measurable by FLC levels, bone marrow plasma cell percentage (percentage must be ≥10%) or definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or soft tissue plasmacytomas, and development of hypercalcemia attributable solely to a plasma cell proliferative disorder. · Phase 2a: Progression-Free Survival (PFS): PFS is the time from the date of first dose to the earliest date of PD. PD is a ≥ 25% increase from the lowest response in any of the following: serum M-protein (increase must be ≥ 0.5 g / dL. If baseline M-protein is ≥ 5 g / dL, an increase in serum M-protein of ≥ 1 g / dL is sufficient to define relapse), and / or urinary M-protein (increase must be ≥ 200 mg / 24 hours), and / or measurable serum and / or urinary M-protein. Difference between abnormal / non-abnormal FLC levels only in participants without measurable levels (increase must be >10 mg / dL), and bone marrow plasma cell percentage (percentage must be ≧10%) or definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or soft tissue plasmacytomas, and development of hypercalcemia attributable only to a plasma cell proliferative disorder, only in participants without measurable serum and / or urinary M-protein levels and without disease measurable by FLC levels. · Phase 2a: Overall Survival (OS): OS is defined as the time from the date of first dose to the date of death from any cause. · Phase 2a: Time to Response (TTR): TTR is defined as the time from the date of first dose to the date of first reported response (partial response (PR) or better). PR is defined as ≥ 50% reduction in serum M-protein and / or ≥ 90% or reduction in 24-hour urinary M-protein to < 200mg / 24hr.
[0366] Inclusion criteria for Phase 1 and Phase 2a studies: Subjects received their last dose of any of the following treatments / procedures within the minimum interval specified before the first dose of AB79: myeloma-specific therapy (30-day washout period), antibody therapy (including anti-CD38) (120-day washout period), corticosteroid therapy (30-day washout period), autologous transplant (90-day washout period), radiation therapy (30-day washout period), major surgery (30-day washout period).
[0367] For participants with MM, measurable disease was defined as one of the following: (a) serum M-protein ≥ 500 mg / dL (≥ 5 g / L); (b) urinary M-protein ≥ 200 mg / 24 hours; or (c) for participants without measurable M-protein on serum protein electrophoresis (SPEP) or urine protein electrophoresis (UPEP), a serum FLC assay result with an involved FLC level ≥ 10 mg / dL (≥ 100 mg / L), provided that the serum FLC ratio was abnormal.
[0368] Prior treatment must meet all of the following criteria: (a) participants previously treated with at least a proteasome inhibitor (PI), an immunomodulatory agent (IMid), an alkylating agent, and a steroid; (b) participants who are refractory or intolerant to at least one PI and at least one IMid; patients must have either received ≥3 prior lines of treatment or at least 2 prior lines of treatment if one of those lines included a combination of a PI and an IMid; (c) participants may have had previous exposure to anti-CD38 agents as single agents or in combination, but this is not required.
[0369] In the phase 2a portion of the study, participants with MM must also be refractory to at least one anti-CD38 monoclonal antibody therapy at any time during treatment. "Refractory" is defined as at least a 25% increase in M protein or PD on treatment or within 60 days after stopping treatment. A "line of treatment" is defined as one or more cycles of a planned treatment program. This may consist of one or more cycles of planned monotherapy or combination therapy, as well as a course of treatment administered in a planned manner. A new line of treatment is initiated when the planned course of treatment is modified to include other therapeutic agents (alone or in combination) as a result of PD, relapse, or toxicity. A new line of treatment is also initiated when a planned observation period off therapy is interrupted by the need for additional treatment for the disease.
[0370] Study Exclusion Criteria: 1. Sensory or motor neuropathy of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade ≥ 3. 2. Have undergone allogeneic stem cell transplantation. 3. Have received anti-CD38 antibody therapy and have not completed the 120-day washout period prior to receiving AB79. 4. Have not recovered from adverse reactions to previous myeloma treatments or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE grade ≤ 1 or baseline. 5. Clinical signs of central nervous system (CNS) involvement in MM. 6. Active chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active HIV, or cytomegalovirus (CMV) infection. 7. POEMS (polyneuropathy, organomegaly, endocrinopathies, monoclonal gammopathy, and skin changes) syndrome, monoclonal gammopathy of undetermined significance, smoldering myeloma, isolated plasmacytoma, amyloidosis, Waldenstrom's macroglobulinemia, or IgM myeloma. 8. Have a positive Coombs test at screening.
[0371] Incorporation by Reference The contents of all cited references (references, patents, patent applications, and websites) that may be cited throughout this application are expressly incorporated herein by reference in their entirety for any purpose, as well as the references cited therein, to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference in its entirety for any purpose.
[0372] Equivalent The present disclosure may be embodied in other specific forms without departing from its spirit or essential characteristics. Therefore, the above-described embodiments should be considered in all respects as illustrative and not limiting of the present disclosure. The scope of the present disclosure is therefore indicated by the appended claims rather than the above description, and all changes that fall within the meaning and range of equivalence of the claims are therefore intended to be embraced by the present disclosure. Modifications for implementing the present invention that are obvious to those skilled in the art are intended to be within the scope of the appended claims.
Claims
1. Use of an isolated human anti-CD38 antibody in the manufacture of a medicament for the treatment of an autoimmune disease in which binding to CD38 is indicated, comprising: the anti-CD38 antibody comprises a variable heavy (VH) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:3, a CDR2 having the amino acid sequence of SEQ ID NO:4, and a CDR3 having the amino acid sequence of SEQ ID NO:5, and a variable light (VL) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:6, a CDR2 having the amino acid sequence of SEQ ID NO:7, and a CDR3 having the amino acid sequence of SEQ ID NO:8; The use wherein the medicament is administered subcutaneously in a dosage of 45 to 600 milligrams.
2. The use described in claim 1, wherein the autoimmune disease is idiopathic thrombocytopenic purpura (ITP).
3. The use described in claim 1, wherein the autoimmune disease is IgA nephropathy (IgAN).
4. The use described in any one of claims 1 to 3, wherein the VH chain region comprises the amino acid sequence of SEQ ID NO: 9 and the VL chain region comprises the amino acid sequence of SEQ ID NO:
10.
5. The use of any one of claims 1 to 4, wherein the anti-CD38 antibody comprises the heavy chain amino acid sequence of SEQ ID NO:11 and the light chain amino acid sequence of SEQ ID NO:
12.
6. The use described in any one of claims 1 to 5, wherein the isolated antibody is AB79.
7. The use of any one of claims 1 to 6, wherein the medicament is administered subcutaneously in a dosage of 100 to 600 milligrams.
8. The use of any one of claims 1 to 7, wherein the medicament is administered subcutaneously in a dosage of 135 to 600 milligrams.
9. The use of any one of claims 1 to 8, wherein the medicament is administered subcutaneously in a dosage of 300 to 600 milligrams.
10. The use of any one of claims 1 to 7, wherein the medicament is administered subcutaneously in a dosage of 100 milligrams.
11. The use of any one of claims 1 to 9, wherein the medicament is administered subcutaneously in a dosage of 300 milligrams.
12. The use of any one of claims 1 to 9, wherein the medicament is administered subcutaneously in a dosage of 600 milligrams.
13. The use according to any one of claims 1 to 12, wherein the medicament is administered subcutaneously once a week.
14. The use according to any one of claims 1 to 12, wherein the medicament is administered subcutaneously twice weekly.
15. The use according to any one of claims 1 to 12, wherein the medicament is administered subcutaneously once every two weeks.
16. The use of any one of claims 1 to 12, wherein the medicament is administered subcutaneously once a month.
17. The use of any one of claims 1 to 16, wherein the isolated antibody does not cause hemolytic anemia or thrombocytopenia.
18. The use of any one of claims 1 to 17, wherein the isolated antibody provides less than 10% of RBCs.
19. The use described in any one of claims 1 to 18, wherein the isolated antibody results in less than 10% of platelets.
20. A formulation for the treatment of an autoimmune disease in which binding to CD38 is indicated, comprising: an isolated antibody comprising a heavy chain variable region comprising SEQ ID NO:9 and a light chain variable region comprising SEQ ID NO:10; the isolated antibody binds to CD38 and does not bind to human erythrocytes; The formulation, wherein the isolated antibody is administered subcutaneously in a dosage of 45 to 600 milligrams.
21. The formulation of claim 20, wherein the autoimmune disease is idiopathic thrombocytopenic purpura (ITP).
22. The formulation of claim 20, wherein the autoimmune disease is IgA nephropathy (IgAN).
23. The formulation of any one of claims 20 to 22, wherein the isolated antibody comprises a heavy chain comprising SEQ ID NO:11 and a light chain comprising SEQ ID NO:
12.
24. The formulation of any one of claims 20 to 23, wherein the isolated antibody is AB79.
25. The formulation of any one of claims 20-24, wherein the isolated antibody is administered subcutaneously in a dosage of 100 to 600 milligrams.
26. The formulation of any one of claims 20-25, wherein the isolated antibody is administered subcutaneously in a dosage of 135 to 600 milligrams.
27. The formulation of any one of claims 20-26, wherein the isolated antibody is administered subcutaneously in a dosage of 300-600 milligrams.
28. The formulation of any one of claims 20-25, wherein the isolated antibody is administered subcutaneously in a dosage of 100 milligrams.
29. The formulation of any one of claims 20-27, wherein the isolated antibody is administered subcutaneously in a dosage of 300 milligrams.
30. The formulation of any one of claims 20-27, wherein the isolated antibody is administered subcutaneously in a dosage of 600 milligrams.
31. The formulation of any one of claims 20-30, wherein the isolated antibody is administered subcutaneously once a week.
32. The formulation of any one of claims 20-30, wherein the isolated antibody is administered subcutaneously twice weekly.
33. The formulation of any one of claims 20-30, wherein the isolated antibody is administered subcutaneously once every two weeks.
34. The use of any one of claims 20 to 30, wherein the isolated antibody is administered subcutaneously once a month.
35. The formulation of any one of claims 20 to 34, wherein the isolated antibody does not cause hemolytic anemia or thrombocytopenia.
36. The formulation of any one of claims 20 to 35, wherein the isolated antibody represents less than 10% of RBCs.
37. The formulation of any one of claims 20 to 36, wherein the isolated antibody yields less than 10% of platelets.
